Distribution Agreement

In presenting this thesis or dissertation as a partial fulfillment of the requirements for an advanced degree from Emory University, I hereby grant to Emory University and its agents the non-exclusive license to archive, make accessible, and display my thesis or dissertation in whole or in part in all forms of media, now or hereafter known, including display on the world wide web. I understand that I may select some access restrictions as part of the online submission of this thesis or dissertation. I retain all ownership rights to the copyright of the thesis or dissertation. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation.

Signature:

Xuan Guang

Date

Associations of Diet and Lifestyle with Cell Cycle Biomarkers in the Normal-appearing Colorectal Mucosa of Colorectal Adenoma Patients

By

Xuan Guang Master of Public Health

Epidemiology

Roberd Bostick, MD, MPH Committee Chair Associations of Diet and Lifestyle with Cell Cycle Biomarkers in the Normal-appearing Colorectal Mucosa of Colorectal Adenoma Patients

By

Xuan Guang

M.Sc. University College London 2016

Thesis Committee Chair: Roberd Bostick, MD, MPH

An abstract of A thesis submitted to the Faculty of the Rollins School of Public Health of Emory University in partial fulfillment of the requirements for the degree of Master of Public Health in Epidemiology 2019

Abstract

Associations of Diet and Lifestyle with Cell Cycle Biomarkers in the Normal-appearing Colorectal Mucosa of Colorectal Adenoma Patients By Xuan Guang

Background

Expression of cell cycle biomarkers of proliferation (Mib-1), differentiation (p21), apoptosis-promotion (BAX) and apoptosis-inhibition (Bcl-2) in the normal-appearing colorectal mucosa were associated with colorectal adenoma. However, there are few data on associations of diet, lifestyle or other factors with expression of these biomarkers in the normal colorectal mucosa of humans.

Methods

We measured Mib-1, p21, BAX, Bcl-2 expression in the normal-appearing rectal mucosa, using automated IHC and image analysis, in a subset of 104 participants in a large chemoprevention trial. Diet was assessed using a Block Brief 2000 Food Frequency Questionnaire. Physical activity was assessed by asking participants how much time they spent in moderate or vigorous activities during the past week. Crosssectional associations of participants' characteristics with the biomarkers at baseline were assessed using multivariable general linear models to compare adjusted mean biomarker expression across categories of the participants' characteristics.

Results

Whole crypt adjusted mean BAX expression was 49.4% higher (P=0.11) among patients with higher relative to lower physical activity. Adjusted Bcl-2 expression was 45.3% lower (P=0.05) among patients with higher relative to lower total calcium intakes. Adjusted Mib-1 expression was 19.4% lower (P=0.10) among patients with higher relative to lower fruit intakes. Adjusted P21 expression was 37.5% higher (P=0.18) among patients with higher relative to lower serum 25-OH vitamin D concentrations.

Conclusions

Our findings support 1) a possible direct association of physical activity with BAX expression; 2) an inverse association of total calcium intake with Bcl-2 expression; 3) inverse associations of fruit intake with Mib-1 expression; and 4) a direct association of serum 25-OH vitamin D concentrations with p21 expression in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients.

Associations of Diet and Lifestyle with Cell Cycle Biomarkers in the Normal-appearing Colorectal Mucosa of Colorectal Adenoma Patients

By

Xuan Guang

M.Sc. University College London 2016

Thesis Committee Chair: Roberd Bostick, MD, MPH

A thesis submitted to the Faculty of the Rollins School of Public Health of Emory University in partial fulfillment of the requirements for the degree of Master of Public Health or Master of Science in Public Health in Epidemiology 2019

Acknowledgements

I would like to express my sincere gratitude to my thesis advisor, Dr. Roberd Bostick, for his guidance and support throughout this project. I would also like to thank my friends and family for their support and encouragement.

Table of Contents

| Introduction | 3 |
|---------------------------------|---|
| Methods | 4 |
| Immunohistochemistry Protocol | 6 |
| Statistical Analysis | 7 |
| Results | 8 |
| Apoptosis-promoting (BAX) | 9 |
| Apoptosis-inhibiting (Bcl- 2)10 | 0 |
| Proliferation (Mib-1)10 | 0 |
| Differentiation (p21)1 | 1 |
| Discussion12 | 2 |
| Apoptosis1 | 3 |
| Proliferation14 | 4 |
| Differentiation1 | 5 |
| Strengths and Limitations1 | 5 |
| Conclusions10 | 6 |
| References1 | 7 |
| Figure | 0 |
| Tables | 1 |
| Supplements | 6 |

Introduction

Colorectal cancer is the second leading cause of cancer-related deaths among men and women combined in the United States. Though the colorectal cancer mortality rate has been dropping in both men and women for several decades due to screening and improving treatment, colorectal cancer is still the third most common cancer diagnosed in the United States. The risk of developing colorectal cancer in women is slightly lower than in men (4.15% vs. 4.49%) (American Cancer Society, 2018).

The evolution of normal colonic mucosa to life-threatening invasive carcinoma involves unbalanced proliferation and apoptosis as well as a number of molecular changes (Mayer, 2012). Pathology examination of the biopsies of gastrointestinal mucosa from colorectal cancer patients revealed aberrant colorectal epithelial cell proliferation, differentiation, and/or decreased apoptosis (Fleming, Ravula, Tatishchev, & Wang, 2012). Altered proliferative patterns are associated with changes in a set of biomarkers: Mib-1, p21^{waf1/cip1}, BAX, and BCL-2.

This set of cell-cycle biomarkers is well supported by basic science literature. BAX promotes apoptosis by controlling mitochondrial outer membrane integrity, while BCL-2, known as B cell lymphoma 2 protein family, inhibits apoptosis (Tait & Green, 2010). BAX gene expression elicits tumor-specific apoptosis of human colon, lung, and cervical cancer cells *in vitro*, and suppressed tumor cell growth *in vivo* (Gu et al., 2000). The Bcl-2 gene family inhibits apoptosis and promotes tumorigenesis. Bcl-2 over-expression was found in a large number of epithelial tumors, such as breast cancer, neuroblastoma, non-small cell lung cancer, and colon cancer (Coultas & Strasser, 2003; Poincloux et al., 2009). Elevated Ki-67 clone Mib-1 was associated with a higher mitotic index and increased proliferation (Martin et al., 2004; Spyratos et al., 2002). p21^{waf1/cip1} is a cyclin-dependent kinase inhibitor that expresses in fully differentiated cells of colorectal crypts (Eldeiry et al., 1995; Fedirko et al., 2009).

Epidemiological evidence suggests that cell cycle biomarkers are associated with colon cancer. A cohort study that followed 168 patients for 15 years reported an inverse association of BAX expression with a '*survivin score*', which reflects the degree of tumor dedifferentiation (Hernandez et al., 2011). Also, higher BCL-2 and Mib-1 expression were associated with advanced tumor grade, clinical stage, and reduced overall survival in colorectal cancer patients (J. S. Wang et al., 2018). The validity of Bcl-2, BAX, Mib-1, and p21 as biomarkers of risk for colorectal neoplasms was supported by the results from a previous pilot case-control study (Bostick, 2015; Fedirko et al., 2009).

Diet is an important risk factor for colorectal adenoma and cancer. Mortality from colorectal cancer is positively associated with the consumption of total energy, red meat, processed meats, and fat (Mayer, 2012). High intakes of fruits, vegetables, fiber, and calcium are associated with lower risk of colorectal cancer (Baron et al., 1999). Low physical activity level, smoking, and alcohol intake are associated with increasing cancer-specific mortality after colorectal cancer diagnosis (Banck-Petersen et al., 2018; Mayer, 2012). All of these findings taken together suggest that higher intakes of fruit, vegetables, and calcium and lower intake of fat may be associated with higher expression of p21 and BAX and lower expression of Mib-1 and Bcl-2 in the normal colorectal mucosa.

Although current literature supports associations of pre-neoplastic biomarkers of risk for colorectal neoplasms with colorectal cancer, few reported studies focused on associations of diet and lifestyle with those biomarkers. In our study, we investigated associations of diet and lifestyle with cell cycle biomarkers in the colorectal epithelium of colorectal adenoma patients.

Methods

The 104 participants in this cross-sectional study were recruited from two of 11 academic medical centers conducting a randomized, double-blind, placebo-controlled chemoprevention clinical trial (n=2,259) designed to test the effects of calcium and vitamin D_3 on colorectal

adenoma recurrence. Enrollment of patients was from July 2004 through July 2008. Eligibility criteria for the clinical trial included being in general good health, aged 45-75, and having at least one histologically-verified neoplastic polyp ≥ 2 mm in diameter removed within 120 days of study entry. We excluded participants with a history of invasive carcinoma, familial colonic polyposis syndromes, and other serious intestinal diseases, serum calcium concentrations outside the normal range, and serum 25(OH)D concentrations <12 ng/ml or >90 ng/ml. All participants provided written informed consent, and the research was approved by the institutional review board at each center.

Participants provided self-reported information regarding demographics, diet (using Block Brief 2000 food frequency questionnaires), lifestyle, and medical history. Physical activity was measured by asking participants how much time they spend on moderate and vigorous activities during the past week, and the results were converted to metabolic equivalents of task minutes (MET). Serum 25(OH)D concentrations were measured using a radioimmunoassay kit from Immunodiagnostic Systems.

Participants underwent "non-prep" (i.e., no prior colon-cleansing preparations) biopsies of normal-appearing rectal mucosa at enrollment. A rigid sigmoidoscope and jumbo cup flexible biopsy forceps mounted on a semi-rigid rod were used to take six approximately 1 mm-thick biopsy specimens from the rectal mucosa 10 cm proximal to the external anal aperture. To avoid possible field effects, all biopsies were taken at least 4 cm from any polypoid lesions. Biopsies were teased onto a strip of bibulous paper and immediately placed in normal saline, oriented, and then transferred to 10% normal buffered formalin for 24 hours; they were then transferred to 70% ethanol, and, within a week, processed and embedded in paraffin blocks (two blocks of three biopsies per participant per biopsy visit). Sufficient biopsy tissue for biomarker measurements was obtained at baseline on 104 patients. (Gao et al., 2018).

Immunohistochemistry Protocol

The four biomarkers—Mib-1, p21, BAX, and Bcl-2—were measured using automated immunohistochemistry and image analysis. First, to uncover epitopes, the slides were placed in a preheated Pretreatment Module (Lab Vision Corp., Fremount, CA) with $100 \times$ Citrate Buffer pH 6.0 (DAKO S1699, DAKO Corp., Carpinteria, CA [hereafter referred to as DAKO]) and steamed for 40 minutes (Gao et al., 2018). The slides were then placed in a DakoCytomation Autostainer Plus System (DAKO) automated immunostainer and immunohistochemically processed using a labeled streptavidin-biotin method (LSAB2 Detection System [DAKO K0675]) for Mib-1, p21, and Bcl-2, and a polymer system (Envision Plus Rabbit System [DAKO K4003]) for BAX. Monoclonal antibodies were used for each biomarker as follows at the following concentrations: Mib-1 (DAKO M7240) – 1:350; p21 (DAKO M7202) – 1:40; BAX (DAKO A3533) – 1:200; and Bcl-2 (Santa Cruz sc-509) – 1:100) (Gao et al., 2018).

Quantifying Staining Density of Immunohistochemically Detected Biomarkers in Colon Crypts Protocol ("Scoring")

A quantitative image analysis procedure ("scoring") was used to describe and measure the detected biomarkers in colon crypts (Figure 1) (Gao et al., 2018). The unit of analysis was a "hemicrypt," defined as one-half of a longitudinally bisected crypt. A crypt defined as "scorable" was one that extended from the muscularis mucosae to the colon lumen(Gao et al., 2018).

The major equipment and software used for the image analysis procedures were: Scanscope CS Digital scanner (Aperio Technologies, Inc., CA), computer, digital drawing board, MatLab Software (MathWorks, Inc., MA), CellularEyes Image Analysis Suite (DivEyes LLC, GA), and MySQL (Sun Microsystems Inc., Santa Clara, CA). Throughout the scoring procedures, standardized settings were used for all equipment, and negative and positive control slides were checked for staining adequacy before analysis (Gao et al., 2018).

First, digital images of the slides were acquired using the Aperio Scanscope CS digital scanner, and then the CellularEyes program was used to review the electronic images and identify colon crypts acceptable for analysis (Gao et al., 2018). Following a strict protocol, trained technicians "scored" hemicrypts for analysis. One technician scored all participants for a given biomarker. The borders of each selected hemicrypt were traced using the digital drawing board, and the program divided the outline into 50 equal-width segments of approximately the average width of normal colonocytes. (Gao et al., 2018). The program then measured the background-corrected optical density of the biomarker labeling across the entire hemicrypt and within each segment. The resulting data were transferred automatically into the MySQL database (Gao et al., 2018). The previously described steps were then repeated for each subsequently identified hemicrypt, with a goal of scoring 32 hemicrypts (Gao et al., 2018). Subsamples of blinded slides were re-scored at intervals and after completing scoring to assess scoring reliability (Gao et al., 2018).

Statistical Analysis

Participants' characteristics were summarized using descriptive statistics, such as means (SD) and proportions as percentages. Continuous variables that were not normally distributed were log transformed to meet normality assumptions. We assessed mean biomarker expression as labeling optical densities within whole crypts, the upper 40% of crypts (differentiation zone), the lower 60% of the crypts (proliferation zone), as well as the ratios of expression in the upper 40% of the crypts to the whole crypts (Φ_h). We also calculated a BAX/BCL-2 ratio to represent the balance of pro- to anti-apoptosis factors, a BAX/Mib-1 ratio to represent the balance of apoptosis to proliferation, and a p21/Mib-1 ratio to represent the balance of differentiation to proliferation.

Continuous exposure variables, such as dietary variables and physical activity, were categorized into tertiles for further data analysis. For total energy, red meat, processed meat, fruit, and dietary fiber intake, tertile categorization was sex specific. Macronutrients were analyzed as percentage of total energy contributed by the macronutrient (e.g., g of fat * 9 kcal /

total energy [kcal]* 100%). Micronutrients were analyzed as nutrient densities (e.g., mg of calcium / 1,000 kcal). Non-aspirin NSAID use was categorized as no current use, < once a week, and \geq once a week. BMI was categorized as < 25, 25 – 29.9, and \geq 30 kg/m².

Multivariable general linear models were used to compare adjusted mean biomarker expression among categories of exposure variables. Potential confounders included sex, age, race, education, smoking, alcohol, physical activity, and multivitamin supplement and non-aspirin NSAID use, BMI, total energy, total fat, saturated fat, red meat, processed meats, fruits, vegetables, dietary fiber, and calcium intakes, 25-(OH)-D concentrations, and selected adenoma characteristics. These potential confounders were assessed through observing whether inclusion/exclusion of these covariates, individually or in combination, affected the magnitude of mean biomarker difference between the upper and lower categories of the exposure variable by $\geq 10\%$. Two-sided P values < 0.05 were considered statistically significant. Statistical analyses were conducted using SAS software, version 9.4 (SAS Institute).

Results

Selected characteristics of the 104 participants are summarized in Table 1. Of the participants, 46% were men, 79% were white, 7.7% were current smokers, 66.4% regularly took a non-aspirin NSAID once a week or more, and 32.7% had multiple adenomas, and 20.4% had an advanced adenoma removed at their most recent colonoscopy. The participants' ages ranged from 47 - 75 years (mean 59 years), their BMIs ranged from 21.0 - 54.1 kg/m² (mean 29.6 kg/m²), and their serum 25-OH-vitamin D concentrations ranged from 12.9 - 68.8 ng/dL (mean 24.1 ng/dL).

Mean expression of BAX, Bcl-2, Mib-1, and p21 in different areas of crypts, by categories of participant characteristics, are presented in Tables 2 - 6. In Table 2 we summarize the strongest findings for all of the biomarkers. The criteria for inclusion in this table were: estimated proportional mean differences in biomarker expression between the highest and lowest categories

of the exposure variable of $\geq 20\%$ and/or a p-value of <0.2, plus at least an approximate doseresponse pattern. More comprehensive findings and exact values are provided in Tables 3 – 6. Findings for the BAX/BCL-2 ratio (ratio of pro to anti-apoptosis), BAX/Mib-1 ratio (ratio of apoptosis to proliferation), the p21/Mib-1 ratio (ratio of differentiation to proliferation), and the ϕ h of crypts for all biomarkers are presented in Supplement Table 2.

Apoptosis-promoting (BAX)

Among those in the highest relative to the lowest tertile of physical activity, mean BAX expression was estimated to be 49.4% (p = 0.11), 95.6% (p = 0.02), 22.6% (p = 0.55), 44.8% (p = 0.11), 95.6% (p = 0.02), 22.6% (p = 0.55), 44.8% (p = 0.11), 95.6% (p = 0.02), 22.6% (p = 0.55), 44.8% (p = 0.11), 95.6% (p = 0.02), 22.6% (p = 0.55), 44.8% (p = 0.11), 95.6% (p = 0.02), 22.6% (p = 0.55), 44.8% (p = 0.11), 95.6% (p = 0.11), 95.6\% (p = 0.12), 95.6\% (p = 0.12) 0.02) higher in the whole, upper 40%, lower 60%, and ϕ h of crypts, respectively (Table 3 and Supplement Table 2). Among those in the highest relative to the lowest tertile of processed meat intake, mean Bax expression was estimated to be 36.2% (p = 0.25) lower in the upper 40% of crypts. Among those in the upper relative to the lower tertile of red meat intake, bax expression was estimated to be 23.8% (p = 0.37) lower in the lower 60% of crypts. Among regular nonaspirin NSAID users, mean bax expression was estimated to be 45.9% (p = 0.27) higher in the upper 40% of crypts and 33.8% (p = 0.11) higher in the ϕh of crypts. Also, among those in the highest relative to the lowest tertile of circulating 25-OH vitamin D concentrations, bax expression was estimated to be 24.4% (p = 0.41), 20.7% (p = 0.66), and 21.5% (p = 0.52) higher in the whole, upper 40% and lower 60% of crypts, respectively. However, among those in the upper relative to the lowest tertile of dietary fiber intake, bax expression was estimated to be lower in all crypt parameters, and among those in the upper tertile of total calcium intake, it was also estimated to be lower in the whole and upper 40% and lower 60% of crypts; none of these estimates was statistically significant.

Apoptosis-inhibiting (Bcl- 2)

Among those in the highest relative to the lowest tertile of total calcium intake, mean Bcl-2 expression was estimated to be 45.3% (p = 0.05), 78.3% (p = 0.20), 41.8% (p = 0.06), 43.9% (p=0.36) lower in the whole, upper 40%, lower 60% and ϕ h of crypts, respectively (Table 4 and Supplement Table 2). Among those use Non-aspirin NSAID more than once a week relative to those do not use Non-aspirin NSAID, mean Bcl-2 expression was estimated to be 45.7% (p = (0.26) and (0.relative to the lowest tertile of current serum 25-OH vitamin D, mean Bcl-2 expression was estimated to be 40.0% (p = 0.64) lower in the upper 40% of crypts. However, among those with relative to without multivitamin supplement use, mean Bcl-2 expression was estimated to be 49.8% (p = 0.04), 86.6% (p = 0.26), 45.7% (p=0.03) higher in the whole, upper 40% and lower 60% of crypts. Among those in the highest relative to the lowest tertile of saturated fat intake, mean Bcl-2 expression was estimated to be 26.3% (p = 0.17) and 25.0% (p = 0.17) lower in the whole and lower 60% of crypts. Among those in the highest relative to the lowest tertile of processed meat, mean Bcl-2 expression was estimated to be 85.2% (p = 0.11) and 30.4% (p = (0.60) lower in the upper 40% and ϕ h of crypts. Among those in the highest relative to the lowest tertile of physical activity and fruit intake, mean Bcl-2 expression was estimated to be 52.6% (p =0.65) and 39.4% (p = 0.83) higher in the upper 40% of crypts. Among those in the highest relative to the lowest tertile of current alcohol intake, mean Bcl-2 expression was estimated to be 44.1% (p = 0.17) lower in the upper 40% of crypts.

Proliferation (Mib-1)

Among those in the highest relative to the lowest tertile of fruit intake, mean Mib-1 expression was estimated to be 19.4% (p = 0.10), 46.1% (p = 0.03), 17.6% (p = 0.15), and 33.0% (p = 0.11) lower in the whole, upper 40%, lower 60%, and ϕ h of crypts, respectively (Table 5 and Supplement Table 2). Among those in the highest relative to the lowest tertile of dietary fiber

intake, mean Mib-1 expression was estimated to be 27.0% (p = 0.02), 24.2% (p = 0.44), and 27.2% (p = 0.02) lower in the whole, upper 40%, and lower 60% of crypts. Among those with relative to without multivitamin supplement use, mean Mib-1 expression was estimated to be 14.2% (p = 0.09), 26.3% (p = 0.12) and 13.4% (p = 0.10) lower in the whole, upper 40%, and lower 60% of crypts. Among those in the highest relative to the lowest tertile of alcohol intake, mean Mib-1 expression was estimated to be 27.6% (p = 0.07), 68.9% (p = 0.10), and 25.7% (p = 0.10) higher in the whole, upper 40%, and lower 60% of crypts. Among those with highest relative to the lowest tertile of total calcium intake, mean Mib-1 expression in the whole, upper 40%, and lower 60% of crypts. Among those with highest relative to the lowest tertile of total calcium intake, mean Mib-1 expression in the whole and upper 40% of crypts was estimated to be 20.6% (p = 0.20) and 44.3% (p = 0.14) lower. Among those with highest relative to the lowest tertile of total fat and processed meat intakes, mean Mib-1 expression in the upper 40% of crypts was estimated to be 20.6% (p = 0.80) and 49.9% (p = 0.37) higher. Among those with highest relative to the lowest tertile of non-aspirin NSAID use, mean Mib-1 expression in the upper 40% of crypts was estimated to be 22.9% (p = 0.71) lower.

Differentiation (p21)

Among those in the highest relative to the lowest tertile of serum 25(OH) vitamin D, mean p21 expression was estimated to be 37.5% (p = 0.18), 34.2% (p = 0.16), and 123.2% (p = 0.22) higher in the whole, upper 40%, and lower 60% of crypts, respectively (Table 6). Mean p21 expression in the lower 60% of crypts was estimated to be 136.9% (p = 0.26) and 36.2% (p = 0.54) higher among those in the highest relative to the lowest tertile of dietary fiber intake and multivitamin supplement use. Mean p21 expression in the lower 60% of crypts was estimated to be 27.2 (p = 0.78), 41.9% (p = 0.29) lower among those in the highest relative to the lowest in the highest relative to the lowest tertile of current alcohol and saturated fat intakes. However, among those in the highest relative to the lowest tertile of non-aspirin NSAID use, mean p21 expression was estimated to be 42.9% (p = 0.50) and 39.6% (p = 0.58) lower in the whole and lower 60% of crypts. Among those in the highest relative to the lowest tertile of the base in the highest relative to the lowest tertile to be 42.9% (p = 0.50) and 39.6% (p = 0.58) lower in the whole and lower 60% of crypts. Among those in the highest relative to the lowest tertile of red meat intake, mean p21 expression was estimated to be

39.7% (p = 0.75) higher in the lower 60% of crypts; none of these estimates was statistically significant.

Discussion

Our results suggest that NSAID use, physical activity, vitamin D exposure, and intakes of calcium, processed meats, fruit, fiber, and alcohol, may be associated with biomarkers of the cell cycle in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients. These associations, although cross-sectional, suggest that the exposures may affect the cell cycle in the colorectal epithelium, and thus risk for colorectal neoplasms, and so support further investigation in larger studies.

More specifically, our results suggest that, based on their estimated associations with bax and bcl-2 expression, the following may be associated with higher apoptosis: NSAID use, higher physical activity, higher vitamin D exposure, and lower alcohol intake. However, our results for apoptosis in relation to saturated fat and red and processed meat intakes were mixed, with red and processed meat intakes being associated with lower bax expression, but with saturated fat and processed meats being associated with lower bcl-2 expression. Similarly, total calcium intakes were associated with lower bcl-2 expression, but also with lower bax expression. Contrary to our hypotheses, higher dietary fiber intake was associated with lower bax expression, and multivitamin/mineral use and higher fruit intakes were associated with higher bcl-2 expression.

Also, our results suggest that, based on their estimated associations with mib-1 expression, the following may be associated with higher colorectal epithelial cell proliferation: alcohol, total fat intake, and processed meat intakes. The following may be associated with lower colorectal epithelial cell proliferation: multivitamin/mineral supplement use, NSAID use, and higher fruit, fiber, and calcium intakes.

Our results also suggest that, based on their estimated associations with p21 expression, the following may be associated with higher colorectal epithelial cell differentiation: higher vitamin

D exposures and calcium and fiber intakes, and lower alcohol, saturated fat and processed meat intakes. However, contrary to our hypotheses, NSAID use was associated with lower p21 expression.

Finally, in this small, preliminary study, we found no strong suggestions that smoking, BMI, or vegetable intakes were associated with the expression of cell cycle biomarkers in the normalappearing colorectal mucosa of adenoma patients.

Apoptosis

As noted above, our results suggest that the following dietary and lifestyle exposures may be associated with bax and bcl-2 expression in ways that suggest that they may increase apoptosis in colorectal crypts: NSAID use, higher physical activity, higher vitamin D exposure, and higher calcium intakes, and to a lesser extent, lower red and processed meat intakes. Impaired apoptosis is one of the hallmarks of colorectal carcinogenesis. NSAID use may induce gastrointestinal cell apoptosis via cyclooxygenase (COX) inhibition, down-regulating the mitochondrial membrane potential, and up-regulating pro-apoptotic BAX, caspase- 8, caspase- 9, and caspase- 3 activity. (Cheng, Lin, Jhang, & Yen, 2019; Musumba, Pritchard, & Pirmohamed, 2009). The underlying mechanisms for possible protective effects of physical activity have not been clearly defined, but may involve decreased expression of COX-2 and INOS in the colon mucosa (Buehlmeyer, Doering, Daniel, Schulz, & Michna, 2007). Vitamin D and calcium may promote apoptosis by modulating the vitamin D receptor and the calcium sensing receptor in mucosa, and activating inflammation signaling (Ahearn et al., 2011; Li, Chen, & Du, 2015). Red and processed meats may reduce apoptosis by heme-induced signaling from surface to crypt cells. Heme in red and processed meat may upregulate the expression of apoptosis inhibitors, including survivin (Birc5), Xiap, and Bcl2 (N et al., 2012).

There are few data on associations or intervention effects of dietary and lifestyle factors with/on apoptosis in the normal-appearing colorectal mucosa of humans. In chemoprevention trials in colorectal adenoma patients, calcium combined with vitamin D increased apoptosis in the normal human colorectal epithelium. In a randomized controlled trial (n = 202 healthy sedentary participants), BAX expression increased (+0.87 log BAX density; p = 0.05) in bottom of crypts of men after 12 months of exercise, a finding that is consistent with our results (Campbell et al., 2007). A second, small randomized trial (N = 20) reported 11.2% (p>0.05) increased BAX expression after 12 weeks physical activity (Dimauro et al., 2016).

Proliferation

As noted above, our results suggest that multiple factors may affect colorectal epithelial cell proliferation. Increased proliferation is one of the hallmarks of colorectal carcinogenesis. Multivitamin/mineral supplement use may decrease proliferation via multiple mechanisms related to the properties of the multiple micronutrients, such as the antioxidant effects of vitamins C and E, beta-carotene, and lutein. Vitamin E may inhibit mucosal cell proliferation by blocking adaptive changes in cell NADH/NAD⁺ redox states and mitochondrial function (Olguin-Martinez, Hernandez-Espinosa, & Hernandez-Munoz, 2013). Fruits may decrease proliferation via the effects of their fiber, antioxidant, and disaccharidase constituents on the human intestinal mucosa (Turco et al., 2016). Alcohol intake may increase proliferation by generating reactive oxygen species (ROS) and inhibiting the expression of antioxidant and cytoprotective enzymes and upregulating the expression of the metabolic activator CYP2E1 (Na & Lee, 2017).

There are few data on associations or intervention effects of dietary and lifestyle factors with/on proliferation in the normal-appearing colorectal mucosa of humans. In chemoprevention trials in colorectal adenoma patients, Mib-1 expression decreased by 24% (p=0.06) in the upper 40% of crypts with supplemental vitamin D3 (1,000 IU/day [25 μ g/day]) and calcium (1,200 mg/day) treatment (Gao et al., 2018). Observational studies also support the association of dietary and lifestyle factors with proliferation. In a cross-sectional study of 44 heavy drinkers and 26 controls found that alcohol abusers had 1.2 – 1.5 times higher proliferative cell nuclear antigen (PCNA) and Mib-1 expression in the lower and middle sections of crypts (Simanowski et al., 2001). In a randomized trial, there were no significant effects of high fruit and vegetable diets on

Mib-1 expression in Barrett's esophagus patients over 36 months (Kristal et al., 2005). In an animal study, reported significant decrease of Mib-1 and Bcl-2 expression significantly decreased with a high dose of fruit peel polyphenols (Kubatka et al., 2016)

Differentiation

As noted above, our results suggest that higher fiber intake, multivitamin supplement use, and vitamin D exposures, lower saturated fat and alcohol intakes may increase differentiation of colorectal crypt epithelial cells. Decreased differentiation is one of the hallmarks of colorectal carcinogenesis. A dietary-induced adenoma model on mouse suggested that western-style diet decreased differentiation and apoptosis in histologically normal villus cells. The altered cell-cycle of villus cells may be caused by inheritance of an *Apc* mutation or inactivation of p21^{WAF1/cip1} (D. Wang et al., 2011; Yang et al., 2001). After 36 weeks of feeding with western diet, the differentiated goblet cells decreased by 25% (p<0.05) in p21^{+/-} type and 39% (p<0.001) in the $p^{21-/-}$ type (Yang et al., 2001).

There are few data on associations or intervention effects of dietary and lifestyle factors with/on epithelial cell differentiation in the normal-appearing colorectal mucosa of humans. In chemoprevention trials in colorectal adenoma patients, calcium and vitamin D alone or combined promoted colorectal crypt epithelial cell differentiation (Gao et al., 2018).

Strengths and Limitations

Strengths of the study include that it is first study of associations of multiple dietary and lifestyle factors with a set of biomarkers profiling cell proliferation, differentiation, and apoptosis within a single study, and the automated immunohistochemistry and novel image analysis methods, which allowed measuring various aspects of the cell cycle in colorectal crypts, the high measurement reliability, and the high protocol adherence by study participants. Limitations include the small sample size; however, as noted, our findings in this pilot study support more

definitive study of dietary and lifestyle factors that may affect the cell cycle in the normalappearing colorectal epithelium, and thus could help favorably modulate risk for colorectal neoplasms. Other limitations include the known limitations of FFQs (recall error, limited number of food items, etc.); however, the Block Brief 2000 is a well-developed, validated FFQ (Delgado et al., 2014). Finally, all study participants were colorectal adenoma patients in a randomized controlled trial, thus potentially limiting the generalizability of our findings to the general population. Another limitation was that we investigated associations of single dietary and lifestyle factors with the biomarkers. It is possible that larger dietary and lifestyle patterns may be more strongly associated with the cell cycle in the colorectal mucosa

Conclusions

In conclusion, our findings, taken in context with those from previous studies, 1) suggest that multiple dietary and lifestyle factors, including NSAID use, physical activity, vitamin D exposure, and intakes of calcium, processed meats, fruit, fiber, and alcohol, may affect the cell cycle in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients, and 2) support their further investigation in larger observational studies and/or intervention trials with cell cycle biomarker and colorectal neoplasm endpoints.

References

Ahearn, T. U., McCullough, M. L., Flanders, W. D., Long, Q., Sidelnikov, E., Fedirko, V., . . . Bostick, R. M. (2011). A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients. *Cancer Research*, 71(2), 413-423. Retrieved from

https://www.ncbi.nlm.nih.gov/pubmed/21084270. doi:10.1158/0008-5472.CAN-10-1560 American Cancer Society. (2018). Key Statistics for Colorectal Cancer. *Cancer Facts & Figures* 2018. Retrieved from https://www.cancer.org/cancer/colon-rectal-cancer/about/key-

- statistics.html
- Banck-Petersen, A., Olsen, C. K., Djurhuus, S. S., Herrstedt, A., Thorsen-Streit, S., Ried-Larsen, M., . . . Christensen, J. F. (2018). The "Interval Walking in Colorectal Cancer" (I-WALK-CRC) study: Design, methods and recruitment results of a randomized controlled feasibility trial. *Contemporary Clinical Trials Communications*, 9, 143-150. Retrieved from <Go to ISI>://WOS:000431064200021. doi:10.1016/j.conctc.2018.01.008
- Baron, J. A., Beach, M., Mandel, J. S., van Stolk, R. U., Haile, R. W., Sandler, R. S., . . . Greenberg, E. R. (1999). Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. *New England Journal of Medicine*, 340(2), 101-107. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/9887161</u>. doi:10.1056/NEJM199901143400204
- Bostick, R. M. (2015). Effects of supplemental vitamin D and calcium on normal colon tissue and circulating biomarkers of risk for colorectal neoplasms. *Journal of Steroid Biochemistry and Molecular Biology*, 148, 86-95. Retrieved from <Go to ISI>://WOS:000351786200015. doi:10.1016/j.jsbmb.2015.01.010
- Buehlmeyer, K., Doering, F., Daniel, H., Schulz, T., & Michna, H. (2007). Exercise associated genes in rat colon mucosa: upregulation of ornithin decarboxylase-1. *Int J Sports Med*, 28(5), 361-367. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/17111318</u>. doi:10.1055/s-2006-924362
- Campbell, K. L., McTiernan, A., Li, S. S., Sorensen, B. E., Yasui, Y., Lampe, J. W., . . . Lampe, P. D. (2007). Effect of a 12-month exercise intervention on the apoptotic regulating proteins Bax and Bcl-2 in colon crypts: a randomized controlled trial. *Cancer Epidemiol Biomarkers Prev*, *16*(9), 1767-1774. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/17855695. doi:10.1158/1055-9965.EPI-07-0291
- Cheng, Y. T., Lin, J. A., Jhang, J. J., & Yen, G. C. (2019). Protocatechuic acid-mediated DJ-1/PARK7 activation followed by PI3K/mTOR signaling pathway activation as a novel mechanism for protection against ketoprofen-induced oxidative damage in the gastrointestinal mucosa. *Free Radic Biol Med*, 130, 35-47. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/30326282</u>. doi:10.1016/j.freeradbiomed.2018.10.415
- Coultas, L., & Strasser, A. (2003). The role of the Bcl-2 protein family in cancer. *Seminars in Cancer Biology*, *13*(2), 115-123. doi:10.1016/s1044-579x(02)00129-3
- Delgado, C., Ward, P., Chertow, G. M., Storer, L., Dalrymple, L., Block, T., . . . Johansen, K. L. (2014). Calibration of the brief food frequency questionnaire among patients on dialysis. *J Ren Nutr*, 24(3), 151-156 e151. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24613023. doi:10.1053/j.jrn.2013.12.004
- Dimauro, I., Scalabrin, M., Fantini, C., Grazioli, E., Beltran Valls, M. R., Mercatelli, N., . . . Caporossi, D. (2016). Resistance training and redox homeostasis: Correlation with ageassociated genomic changes. *Redox Biol*, 10, 34-44. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/27687219</u>. doi:10.1016/j.redox.2016.09.008

- Eldeiry, W. S., Tokino, T., Waldman, T., Oliner, J. D., Velculescu, V. E., Burrell, M., . . . Vogelstein, B. (1995). Topological Control of P21(Waf1/Cip1) Expression in Normal and Neoplastic Tissues. *Cancer Research*, 55(13), 2910-2919. Retrieved from <Go to ISI>://WOS:A1995RF49600034.
- Fedirko, V., Bostick, R. M., Flanders, W. D., Long, Q., Sidelnikov, E., Shaukat, A., . . . Woodard, J. J. (2009). Effects of Vitamin D and Calcium on Proliferation and Differentiation In Normal Colon Mucosa: a Randomized Clinical Trial. *Cancer Epidemiology Biomarkers & Prevention*, 18(11), 2933-2941. Retrieved from <Go to ISI>://WOS:000271562600020. doi:10.1158/1055-9965.Epi-09-0239
- Fleming, M., Ravula, S., Tatishchev, S. F., & Wang, H. L. (2012). Colorectal carcinoma: Pathologic aspects. *Journal of Gastrointestinal Oncology*, 3(3), 153-173. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/22943008</u>. doi:10.3978/j.issn.2078-6891.2012.030
- Gao, Y., Um, C. Y., Fedirko, V., Rutherford, R. E., Seabrook, M. E., Barry, E. L., . . . Bostick, R. M. (2018). Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients. *PLoS One*, *13*(12), e0208762. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30557404. doi:10.1371/journal.pone.0208762
- Gu, J., Kagawa, S., Takakura, M., Kyo, S., Inoue, M., Roth, J. A., & Fang, B. (2000). Tumorspecific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. *Cancer Research*, 60(19), 5359-5364. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11034071.
- Kristal, A. R., Blount, P. L., Schenk, J. M., Sanchez, C. A., Rabinovitch, P. S., Odze, R. D., ...
 Reid, B. J. (2005). Low-fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus. *Cancer Epidemiol Biomarkers Prev*, *14*(10), 2377-2383. Retrieved from

https://www.ncbi.nlm.nih.gov/pubmed/16214920. doi:10.1158/1055-9965.EPI-05-0158

- Kubatka, P., Kapinová, A., Kello, M., Kruzliak, P., Kajo, K., Výbohová, D., . . . Mojžiš, J. (2016). Fruit peel polyphenols demonstrate substantial anti-tumour effects in the model of breast cancer. *European journal of nutrition*, 55(3), 955-965.
- Li, Y. C., Chen, Y., & Du, J. (2015). Critical roles of intestinal epithelial vitamin D receptor signaling in controlling gut mucosal inflammation. *The Journal of steroid biochemistry and molecular biology, 148*, 179-183.
- Martin, B., Paesmans, M., Mascaux, C., Berghmans, T., Lothaire, P., Meert, A. P., ... Sculier, J. P. (2004). Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. *British Journal of Cancer*, *91*(12), 2018-2025. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/15545971</u>. doi:10.1038/sj.bjc.6602233
- Mayer, R. J. (2012). Chapter 91. Gastrointestinal Tract Cancer. In D. L. Longo, A. S. Fauci, D. L. Kasper, S. L. Hauser, J. L. Jameson, & J. Loscalzo (Eds.), *Harrison's Principles of Internal Medicine, 18e.* New York, NY: The McGraw-Hill Companies.
- Musumba, C., Pritchard, D. M., & Pirmohamed, M. (2009). Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. *Aliment Pharmacol Ther*, 30(6), 517-531. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/19575764</u>. doi:10.1111/j.1365-2036.2009.04086.x
- N, I. J., Rijnierse, A., de Wit, N., Jonker-Termont, D., Dekker, J., Muller, M., & van der Meer, R. (2012). Dietary haem stimulates epithelial cell turnover by downregulating feedback inhibitors of proliferation in murine colon. *Gut*, 61(7), 1041-1049. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/21948946</u>. doi:10.1136/gutjnl-2011-300239
- Na, H. K., & Lee, J. Y. (2017). Molecular Basis of Alcohol-Related Gastric and Colon Cancer. Int J Mol Sci, 18(6). Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/28538665</u>. doi:10.3390/ijms18061116

- Olguin-Martinez, M., Hernandez-Espinosa, D. R., & Hernandez-Munoz, R. (2013). alpha-Tocopherol administration blocks adaptive changes in cell NADH/NAD+ redox state and mitochondrial function leading to inhibition of gastric mucosa cell proliferation in rats. *Free Radic Biol Med*, 65, 1090-1100. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/23994576</u>. doi:10.1016/j.freeradbiomed.2013.08.176
- Poincloux, L., Durando, X., Seitz, J. F., Thivat, E., Bardou, V. J., Giovannini, M. H., ... Monges, G. (2009). Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. *Surg Oncol, 18*(4), 357-365. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19027288. doi:10.1016/j.suronc.2008.09.003
- Simanowski, U., Homann, N., Knühl, M., Arce, L., Waldherr, R., Conradt, C., ... Seitz, H. (2001). Increased rectal cell proliferation following alcohol abuse. *Gut*, 49(3), 418-422.
- Spyratos, F., Ferrero-Pous, M., Trassard, M., Hacene, K., Phillips, E., Tubiana-Hulin, M., & Le Doussal, V. (2002). Correlation between MIB-1 and other proliferation markers - Clinical implications of the MIB-1 cutoff value. *Cancer*, 94(8), 2151-2159. Retrieved from <Go to ISI>://WOS:000175062700005. doi:10.1002/cncr.10458
- Tait, S. W. G., & Green, D. R. (2010). Mitochondria and cell death: outer membrane permeabilization and beyond. *Nature Reviews Molecular Cell Biology*, 11(9), 621-632. Retrieved from <Go to ISI>://WOS:000281192800011. doi:10.1038/nrm2952
- Turco, F., Palumbo, I., Andreozzi, P., Sarnelli, G., De Ruberto, F., Esposito, G., . . . Cuomo, R. (2016). Acetonic Extract from the Feijoa sellowiana Berg. Fruit Exerts Antioxidant Properties and Modulates Disaccharidases Activities in Human Intestinal Epithelial Cells. *Phytother Res*, *30*(8), 1308-1315. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27166598. doi:10.1002/ptr.5629
- Wang, D., Peregrina, K., Dhima, E., Lin, E. Y., Mariadason, J. M., & Augenlicht, L. H. (2011). Paneth cell marker expression in intestinal villi and colon crypts characterizes dietary induced risk for mouse sporadic intestinal cancer. *Proc Natl Acad Sci U S A*, 108(25), 10272-10277. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/21652773</u>. doi:10.1073/pnas.1017668108
- Wang, J. S., He, G., Yang, Q., Bai, L., Jian, B., Li, Q. G., & Li, Z. F. (2018). B-cell lymphoma 2 is associated with advanced tumor grade and clinical stage, and reduced overall survival in young Chinese patients with colorectal carcinoma. *Oncology Letters*, 15(6), 9009-9016. Retrieved from <Go to ISI>://WOS:000435149700105. doi:10.3892/ol.2018.8489
- Yang, W. C., Mathew, J., Velcich, A., Edelmann, W., Kucherlapati, R., Lipkin, M., . . . Augenlicht, L. H. (2001). Targeted inactivation of the p21WAF1/cip1 gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style highrisk diet by altering cell maturation in the intestinal mucosa. *Cancer Research*, 61(2), 565-569.

Figure




Figure 1. Depicts image analysis biomarker (p21) expression in crypts of normal-appearing rectal mucosa using custom-designed quantitative image analysis software. [A] A full length hemicrypt is identified. [B] The hemicrypt is manually outlined. [C] p21 labeling optical density is quantified, overall and within each of the 50 segments of the hemicrypt.

| | Mean or | | |
|--|------------|-------|--------------|
| Characteristic | proportion | SD | Range |
| Demographics | | | |
| Age (yr.) | 58.9 | 6.7 | 47 - 75 |
| Male (%) | 46.2 | | |
| White (%) | 78.9 | | |
| \geq High school education (%) | 81.7 | | |
| Lifestyle and medical history | | | |
| Currently smoke (%) | 7.7 | | |
| Alcohol (drinks/day) | 0.7 | 0.9 | 0.0 - 3.6 |
| Multivitamin supplement (n/week) | 4.7 | 3.3 | 0 - 7 |
| Take non-aspirin NSAID (%) ^b | 66.4 | | |
| BMI (kg/m^2) | 29.6 | 5.6 | 21.0 - 54.1 |
| Physical activity (MET-min/week) | 2,472 | 2,484 | 0 - 15,198 |
| Dietary intakes | | | |
| Total energy (kcal/day) | 1,456 | 554 | 630 - 2,936 |
| Total fat (g/day) | 59.6 | 28.1 | 15.8 - 145.7 |
| Saturated fat (g/day) | 19.2 | 9.5 | 5.0 - 46.0 |
| Red meat (servings/day) | 0.5 | 0.5 | 0 - 2.3 |
| Processed meat (servings/day) | 0.3 | 0.4 | 0 - 2.3 |
| Fruits (servings/day) | 1.3 | 0.7 | 0.1 - 3.6 |
| Vegetables (serving/day) | 3.4 | 1.9 | 0.6 - 11.7 |
| Dietary fiber (gm/day) | 14.6 | 5.7 | 3.8 - 32.2 |
| Total calcium (mg/d) ^c | 879 | 450 | 213 - 2,512 |
| Serum concentration | | | |
| 25-OH vitamin D (ng/ml) | 24.1 | 9.3 | 12.9-68.8 |
| Cell cycle biomarkers expression (OD) ^d | | | |
| BAX (apoptosis-promoting) | 446 | 118 | 31 - 2,756 |
| Bcl-2 (apoptosis-inhibiting) | 796 | 474 | 157 - 2,583 |
| Mib-1 (proliferation) | 1,267 | 518 | 416 - 3,302 |
| p21 (differentiation) | 708 | 435 | 166 - 2,680 |
| Adenoma | | | |
| >1 adenoma (%) | 32.7 | | |
| Advanced adenoma (%) | 20.4 | | |

Tables Table 1. Selected characteristics of the study participants (n = 104)^a

Abbreviations: BMI, body mass index; MET, metabolic equivalent of task; NSAID, nonsteroidal anti-inflammatory drug; OD, optical density.

^a Data are given as means (SD) unless otherwise specified

^b Regularly take non-aspirin nonsteroidal anti-inflammatory drug at least once a week

^c Dietary plus supplemental calcium intake

^d Optical density of biomarker expression in whole crypts of normal-appearing rectal mucosa

| | | BA | Х | | | Bcl | -2 | | | Mit |) -1 | | P21 ^b | | |
|--------------------------------------|-----------------|---------------------------|---------------------------|-----------------|-----------------|---------------------------|---------------------------|-----------------|-----------------|---------------------------|--------------------------|-----------------|------------------|---------------------------|--------------------------|
| Participants characteristics | Whole crypts | Upper 40% of crypts | Lower 60% of crypts | φh ^c | Whole crypts | Upper 40% of crypts | Lower 60% of crypts | $\phi h^{ m c}$ | Whole crypts | Upper 40% of crypts | Lower 60% of crypt | φh ^c | Whole crypt | Upper 40% of crypts | Lower 60% of crypt |
| Lifestyle and medical history | | | | | | | | | | | | | | | |
| Current alcohol intake | | | | | | (↓) | | | ↑ | ↑ | ↑ | | | | Ļ |
| Multivitamin supplement use | | | | | (†)* | (†) | (†)* | | Ļ | Ļ | Ļ | | | | ¢ |
| Regularly take non- aspirin NSAID | | ↑ | | Ţ | | Ļ | | ↓ | | Ļ | | | (↓) | | (↓) |
| Physical activity | 1 | \uparrow^* | 1 | Ť | | (↑) | | | | | | | | | |
| Dietary intakes | | | | | | | | | | | | | | | |
| Total fat | | | | | | | | | | Ŷ | | | | | |
| Saturated fat | | | | | (↓) | | (↓) | | | | | | | | Ļ |
| Red meat | | | \downarrow | | | | | | | | | | | | (†) |
| Processed meat | | \downarrow | | | | (↓) | | (↓) | | Ŷ | | | | | |
| Fruit | | | | | | (†) | | | Ļ | \downarrow^* | \downarrow | \downarrow | | | |
| Dietary fiber | (↓) | (\downarrow) | (↓) | (↓) | | | | | ↓* | \downarrow | \downarrow^* | | | | ↑ |
| Total calcium | (↓) | (\downarrow) | (↓) | | \downarrow^* | Ļ | \downarrow | \downarrow | Ļ | \downarrow | | | | | |
| Serum concentrations | | | | | | | | | | | | | | | |
| 25-OH Vitamin D | î | 1 | 1 | | | \downarrow | | | | | | | ſ | ↑ | ↑ |

Table 2. Summary of differences ^a in mean cell cycle biomarker expression in the normal-appearing colorectal mucosa, across categories of selected participant characteristics.

Abbreviations: MET, metabolic equivalent of task; NSAID, nonsteroidal anti-inflammatory drug.

^a Criteria for inclusion in this table are: estimated proportional mean difference $\geq 20\%$ and/or a p-value < 0.2 for the estimated difference. Up/down arrows indicate the direction (higher or lower, respectively) of the mean biomarker difference between a higher relative to the reference exposure category. Arrows in brackets [e.g., (\uparrow)] indicate that the direction of the difference was opposite that hypothesized. * Indicates a statistically significant (p < 0.05) finding.

^b p21 ϕh is not included in this table because no findings met the criteria for inclusion

 $^{\circ} \phi h$ is the ratio of mean biomarker expression in upper 40% of crypts relative to that in whole crypts

| | | Who | e crypts | | Up | per 4 | 0% of crypts | | Lower 60% of crypts | | | | |
|-------------------------------------|---|-------|---|-------------------|---|-------|---|------------|---|------|---|------------|--|
| Participant characteristics | Mean biomarker expression (OD) | | Proportional difference ^b | <i>P</i> value | Mean biomarker expression (OD) | | Proportional difference ^b | P value | Mean biomarker expression (OD) | SE | Proportional difference ^b | P value | |
| Current alcohol intake ^f | | | - | · · · | (-) | | | | | | | | |
| None | 477.9 | 60.4 | | | 148.7 | 25.9 | | | 335.6 | 39.8 | | | |
| Low | 358.6 | 54.6 | -25.0% | 0.25 | 133.7 | 23.4 | -10.0% | 0.87 | 226.7 | 35.9 | -32.4% | 0.08 | |
| High | 454.7 | 60.9 | -4.9% | 0.95 | 167.9 | 26.1 | 12.9% | 0.83 | 278.5 | 40.1 | -17.0% | 0.51 | |
| Multivitamin use | | | | | | | | | | | | | |
| No | 416.5 | 398.6 | | | 139.9 | 25.3 | | | 258.7 | 39.8 | | | |
| Yes | 442.6 | 438.6 | 6.3% | 0.73 | 153.6 | 17.5 | 9.8% | 0.66 | 285.0 | 27.5 | 10.2% | 0.60 | |
| Non-aspirin NSAID use | | | | | | | | | | | | | |
| None | 454.4 | 58.6 | | | 145.5 | 24.5 | | | 292.1 | 39.3 | | | |
| Once a week | 405.3 | 47.7 | -10.8% | 0.77 | 135.0 | 19.9 | -7.2% | 0.95 | 265.5 | 32.0 | -9.1% | 0.83 | |
| > once a week | 487.3 | 92.9 | 7.3% | 0.94 | 212.3 | 38.8 | 45.9% | 0.27 | 276.2 | 62.3 | -5.5% | 0.97 | |
| Physical activity ^d | | | | | | | | | | | | | |
| Low | 354.0 | 65.9 | | | 106.4 | 27.5 | | | 250.4 | 43.9 | | | |
| Medium | 407.9 | 59.5 | 15.2% | 0.77 | 126.1 | 24.8 | | 0.81 | 271.2 | 39.6 | 8.3% | 0.91 | |
| High | 528.9 | 60.7 | 49.4% | 0.11 | 208.0 | 25.3 | | 0.02 | 307.0 | 40.4 | 22.6% | 0.55 | |
| Total fat intake | | | | | | | | | | | | | |
| Low | 445.9 | 59.4 | | | 151.5 | 25.2 | | | 270.2 | 39.7 | | | |
| Medium | 415.7 | 58.0 | -6.8% | 0.91 | 142.6 | 24.6 | -5.9% | 0.98 | 283.7 | 38.7 | 5.0% | 0.96 | |
| High | 440.1 | 60.9 | -1.3% | 1.00 | 153.5 | 25.8 | 1.4% | 0.61 | 274.8 | 40.7 | 1.7% | 1.00 | |
| Saturated fat intake | | | | | | | | | | | | | |
| Low | 501.0 | 56.1 | | | 176.7 | 24.1 | | | 321.1 | 37.7 | | | |
| Medium | | 57.3 | -36.9% | 0.05 | 102.8 | 24.6 | | 0.07 | 198.5 | 38.5 | -38.2% | 0.05 | |
| High | 473.0 | 56.1 | -5.6% | 0.92 | 164.5 | 24.1 | | 0.91 | 303.9 | 37.7 | -5.3% | 0.93 | |
| e | | | | | | | | | | | | | |

Table 3. BAX expression in crypts of normal-appearing rectal mucosa of sporadic colorectal adenoma patients according to categories of participant characteristics (n = 104)^a.

| Red meat intake | | | | | | | | | | | | |
|-----------------------------------|-------|------|--------|------|-------|------|--------|------|-------|------|--------|------|
| Low | 451.4 | 58.1 | | | 146.5 | 25.1 | | | 309.6 | 39.9 | | |
| Medium | 479.3 | 60.9 | 6.2% | 0.93 | 171.9 | 25.9 | 17.3% | 0.71 | 281.3 | 41.1 | -9.1% | 0.84 |
| High | 366.0 | 62.8 | -18.9% | 0.54 | 130.0 | 26.1 | -11.2% | 0.87 | 235.8 | 41.5 | -23.8% | 0.37 |
| Processed meat intake | | | | | | | | | | | | |
| Low | 445.7 | 65.5 | | | 185.9 | 27.5 | | | 275.4 | 43.9 | | |
| Medium | 417.9 | 59.0 | -6.3% | 0.93 | 141.5 | 24.7 | -23.9% | 0.35 | 272.0 | 39.6 | -1.3% | 1.00 |
| High | 437.5 | 71.8 | -1.8% | 1.00 | 118.5 | 30.1 | -36.2% | 0.25 | 281.7 | 48.2 | 2.3% | 0.99 |
| Fruit intake | | | | | | | | | | | | |
| Low | 463.4 | 65.4 | | | 150.3 | 27.8 | | | 288.9 | 43.7 | | |
| Medium | 423.9 | 57.2 | -8.5% | 0.87 | 148.4 | 24.3 | -1.3% | 1.00 | 275.2 | 38.2 | -4.8% | 0.96 |
| High | 422.5 | 55.0 | -8.8% | 0.85 | 148.9 | 23.4 | -0.9% | 1.00 | 268.5 | 36.8 | -7.1% | 0.91 |
| Dietary fiber intake | | | | | | | | | | | | |
| Low | 509.0 | 63.3 | | | 158.2 | 26.9 | | | 329.7 | 42.1 | | |
| Medium | 415.9 | 58.1 | -18.3% | 0.45 | 164.8 | 24.7 | 4.2% | 0.98 | 248.6 | 38.6 | -24.6% | 0.27 |
| High | 374.2 | 63.9 | -26.5% | 0.28 | 124.0 | 27.2 | -21.7% | 0.61 | 248.8 | 42.5 | -24.5% | 0.35 |
| Total calcium intake ^e | | | | | | | | | | | | |
| Low | 520.8 | 65.9 | | | 174.7 | 28.2 | | | 319.3 | 43.7 | | |
| Medium | 405.9 | 63.1 | -22.1% | 0.37 | 154.1 | 27.0 | -11.8% | 0.82 | 261.6 | 41.8 | -18.0% | 0.53 |
| High | 395.9 | 67.3 | -24.0% | 0.37 | 134.2 | 28.8 | -23.2% | 0.54 | 249.4 | 44.6 | -21.9% | 0.47 |
| Serum 25-OH vitamin D^{f} | | | | | | | | | | | | |
| Low | 421.3 | 51.0 | | | 138.0 | 21.7 | | | 265.9 | 34.1 | | |
| Medium | 389.7 | 60.8 | -7.5% | 0.90 | 151.6 | 25.9 | 9.9% | 0.90 | 257.2 | 40.6 | -3.3% | 0.98 |
| High | 524.3 | 69.6 | 24.4% | 0.41 | 166.6 | 29.7 | 20.7% | 0.66 | 323.2 | 46.5 | 21.5% | 0.52 |
| | | | | | | | | | | | | |

Abbreviations: OD, optical density; SE, standard error; NSAID, nonsteroidal anti-inflammatory drug.

^a Results presented as geometric means, adjusted for batch, age, race, total calcium, and total energy intake, multivitamin supplement use, non-aspirin NSAID use, and adenoma characteristics.

^b Proportional difference defined as [(comparison group mean - reference group mean) / reference group mean] *100%.

^c P value for the difference between the comparison group and the reference group, from multivariable general linear model.

^d Physical activity was measured by asking participants how much time they spend on moderate and vigorous activities during the past week, the results were converted to metabolic equivalents of task minutes (MET).

^e Total calcium defined as dietary calcium plus supplement calcium intake. ^fLow, medium, and high categories were defined as: current alcohol intake (drinks/day), none, ≤ 0.8 , >0.8; Serum 25-OH vitamin D $(ng/ml), <20, 20-30, \ge 30;$

| | | Who | le crypts | | Up | oper 40 |)% of crypts | | Lo | ower 6 | 0% of crypts | |
|--|---|-------|---|------|---|---------|---|------|---|--------|--|------|
| Participant characteristics | Mean biomarker expression (OD) | | Proportional difference ^b | | Mean biomarker expression (OD) | SE | Proportional difference ^b | | Mean biomarker expression (OD) | | Proportional difference ^b | |
| Current alcohol intake ^f | | | | | | | | | | | | |
| None | 745.5 | 112.1 | | | 78.8 | 24.8 | | | 688.5 | 96.6 | | |
| Low | 955.6 | 96.8 | 28.2% | 0.32 | 77.6 | 21.4 | -1.6% | 1.00 | 858.5 | 84.2 | 24.7% | 0.35 |
| High | 791.7 | 105.1 | 6.2% | 0.94 | 44.1 | 23.3 | -44.1% | 0.52 | 737.1 | 91.7 | 7.1% | 0.92 |
| Multivitamin use | | | | | | | | | | | | |
| No | 632.7 | 109.9 | | | 42.9 | 24.0 | | | 589.2 | 92.9 | | |
| Yes | 947.9 | 73.2 | 49.8% | 0.04 | 80.1 | 16.0 | 86.6% | 0.26 | 858.6 | 62.5 | 45.7% | 0.03 |
| Non-aspirin NSAID use | | | | | | | | | | | | |
| None | 1,029.9 | 211.5 | | | 119.1 | 46.8 | | | 908.2 | 84.8 | | |
| Once a week | 707.1 | 75.5 | -31.3% | 0.03 | 36.9 | 16.7 | -69.0% | 0.01 | 672.2 | 63.2 | -26.0% | 0.07 |
| > once a week | 877.4 | 349.3 | -14.8% | 0.57 | 64.6 | 77.3 | -45.7% | 0.26 | 791.6 | 119.9 | -12.8% | 0.66 |
| Physical activity ^d | | | | | | | | | | | | |
| Low | 711.3 | 107.4 | | | 47.8 | 23.8 | | | 664.9 | 93.4 | | |
| Medium | 936.9 | 93.8 | 31.7% | 0.21 | 79.7 | 20.8 | 66.8% | 0.51 | 854.0 | 81.3 | 28.4% | 0.24 |
| High | 847.3 | 92.3 | 19.1% | 0.55 | 72.9 | 20.5 | 52.6% | 0.65 | 776.3 | 80.3 | 16.8% | 0.59 |
| Total fat intake | | | | | | | | | | | | |
| Low | 819.7 | 95.8 | | | 57.1 | 21.8 | | | 762.6 | 82.9 | | |
| Medium | 1,023.7 | 91.4 | 24.9% | 0.20 | 86.4 | 20.8 | 51.5% | 0.50 | 937.2 | 79.1 | 22.9% | 0.21 |
| High | 660.5 | 101.4 | -19.4% | 0.48 | 58.2 | 23.0 | 2.0% | 1.00 | 602.3 | 87.7 | -21.0% | 0.38 |
| Saturated fat intake | | | | | | | | | | | | |
| Low | 957.0 | 98.6 | | | 72.0 | 21.5 | | | 885.0 | 85.7 | | |

Table 4. Bcl-2 expression in crypts of normal-appearing rectal mucosa of sporadic colorectal adenoma patients according to categories of participant characteristics (n = 104)^a.

| Medium | 846.3 | 95.6 | -11.6% | 0.63 | 92.0 | 20.8 | 27.8% | 0.72 | 754.3 | 83.1 | -14.8% | 0.44 |
|---------------------------------------|-------|-------|--------|------|-------|------|--------|------|-------|-------|--------|------|
| High | 705.5 | 97.6 | -26.3% | 0.17 | 41.8 | 21.3 | -42.0% | 0.56 | 663.7 | 84.8 | -25.0% | 0.17 |
| Red meat intake | | | | | | | | | | | | |
| Low | 897.6 | 103.4 | | | 70.5 | 22.5 | | | 827.1 | 89.8 | | |
| Medium | 788.1 | 99.4 | -12.2% | 0.67 | 53.8 | 21.7 | -23.7% | 0.82 | 734.3 | 86.4 | -11.2% | 0.69 |
| High | 810.9 | 101.2 | -9.7% | 0.80 | 76.5 | 22.0 | 8.5% | 0.98 | 734.4 | 87.9 | -11.2% | 0.71 |
| Processed meat intake | | | | | | | | | | | | |
| Low | 873.4 | 107.4 | | | 91.9 | 23.5 | | | 773.1 | 96.1 | | |
| Medium | 927.3 | 102.7 | 6.2% | 0.91 | 100.7 | 22.5 | 9.6% | 0.95 | 834.9 | 91.0 | 8.0% | 0.85 |
| High | 711.9 | 118.3 | -18.5% | 0.59 | 13.6 | 25.9 | -85.2% | 0.11 | 700.5 | 104.6 | -9.4% | 0.87 |
| Fruit intake | | | | | | | | | | | | |
| Low | 707.7 | 112.2 | | | 40.8 | 24.2 | | | 666.9 | 98.1 | | |
| Medium | 941.3 | 92.2 | 33.0% | 0.22 | 98.2 | 19.9 | 140.9% | 0.15 | 843.0 | 80.6 | 26.4% | 0.31 |
| High | 820.8 | 92.1 | 16.0% | 0.66 | 56.9 | 19.9 | 39.4% | 0.83 | 763.9 | 80.5 | 14.5% | 0.67 |
| Dietary fiber intake | | | | | | | | | | | | |
| Low | 809.5 | 109.6 | | | 51.5 | 22.6 | | | 758.0 | 96.1 | | |
| Medium | 923.8 | 93.7 | 14.1% | 0.65 | 113.0 | 19.3 | 119.4% | 0.09 | 810.8 | 82.2 | 7.0% | 0.88 |
| High | 750.1 | 130.2 | -7.3% | 0.93 | 31.6 | 26.9 | -38.7% | 0.83 | 718.5 | 114.1 | -5.2% | 0.96 |
| Total calcium intake ^e | | | | | | | | | | | | |
| Low | 981.6 | 119.1 | | | 87.4 | 26.2 | | | 894.5 | 103.7 | | |
| Medium | 978.8 | 94.9 | -0.3% | 1.00 | 95.3 | 20.9 | 9.0% | 0.96 | 880.7 | 82.6 | -1.5% | 0.99 |
| High | 537.1 | 119.0 | -45.3% | 0.05 | 18.9 | 26.2 | -78.3% | 0.20 | 520.6 | 103.7 | -41.8% | 0.06 |
| Serum 25-OH vitamin D ^f | | | | | | | | | | | | |
| Low | 880.0 | 88.3 | | | 78.3 | 19.3 | | | 799.5 | 76.8 | | |
| Medium | 835.6 | 95.7 | -5.1% | 0.92 | 65.9 | 20.9 | -15.8% | 0.88 | 766.8 | 83.2 | -4.1% | 0.94 |
| High | 733.2 | 134.1 | -16.7% | 0.62 | 47.0 | 29.1 | -40.0% | 0.64 | 694.7 | 116.7 | -13.1% | 0.73 |

Abbreviations: OD, optical density; SE, standard error; NSAID, nonsteroidal anti-inflammatory drug.

^aResults presented as geometric means, adjusted for batch, age, race, total calcium, and total energy intake, multivitamin supplement use, non-aspirin NSAID use, and adenoma characteristics.

^bProportional difference defined as [(comparison group mean - reference group mean) / reference group mean] *100%.

^cP value for the difference between the comparison group and the reference group, from multivariable general linear model.

^dPhysical activity was measured by asking participants how much time they spend on moderate and vigorous activities during the past week, the results were converted to metabolic equivalents of task minutes (MET).

^eTotal calcium defined as dietary calcium plus supplement calcium intake.

^f Low, medium, and high categories were defined as: current alcohol intake (drinks/day), none, ≤ 0.8 , >0.8; Serum 25-OH vitamin D (ng/ml), $< 20, 20 - 30, \geq 30$;

| | | Who | le crypts | | Up | oper 40 | 0% of crypts | | Lo | ower 6 | 0% of crypts | |
|--------------------------------|---|-------|---|-------|---|---------|---|------|---|--------|---|------|
| Participant characteristics | Mean biomarker expression (OD) | | Proportional difference ^b | | Mean biomarker expression (OD) | SE | Proportional difference ^b | | Mean biomarker expression (OD) | SE | Proportional difference ^b | |
| Current alcohol | | | | | · · · | | | | · · · · | | | |
| intake ^f | | | | | | | | | | | | |
| | 1,119.9 | 101.4 | | | 50.6 | 12.2 | | | 1,069.4 | 96.0 | | |
| Low | 1,179.6 | 85.4 | 5.3% | 0.86 | 60.5 | 10.3 | 19.7% | 0.76 | 1,119.1 | 80.9 | 4.6% | 0.89 |
| High | 1,429.1 | 97.5 | 27.6% | 0.07 | 85.4 | 11.8 | 68.9% | 0.10 | 1,343.7 | 92.3 | 25.7% | 0.10 |
| Multivitamin use | | | | | | | | | | | | |
| No | 1,370.9 | 91.5 | | | 79.4 | 11.0 | | | 1,291.5 | 86.3 | | |
| Yes | 1,176.5 | 64.0 | -14.2% | 0.09 | 58.5 | 7.7 | -26.3% | 0.12 | 1,118.0 | 60.4 | -13.4% | 0.10 |
| Non-aspirin NSAID use | | | | | | | | | | | | |
| None | 1,323.9 | 90.5 | | | 64.4 | 10.9 | | | 1,259.5 | 85.3 | | |
| Once a week | 1,205.8 | 74.5 | -8.9% | 0.52 | 70.1 | 8.9 | 8.9% | 0.89 | 1,135.6 | 70.2 | -9.8% | 0.45 |
| > once a week | | 146.7 | -12.9% | 0.53 | 49.7 | 17.6 | -22.9% | 0.71 | 1,103.4 | 138.3 | -12.4% | 0.55 |
| Physical activity ^d | | | | | | | | | | | | |
| Low | 1,157.6 | 104.3 | | | 63.8 | 12.6 | | | 1,093.8 | 98.3 | | |
| Medium | 1,317.9 | 92.5 | 13.8% | 0.42 | 71.9 | 11.2 | 12.6% | 0.85 | 1,246.1 | 87.2 | 13.9% | 0.41 |
| High | 1,242.6 | 92.0 | 7.3% | 0.77 | 60.7 | 11.1 | -4.8% | 0.98 | 1,181.9 | 86.7 | 8.1% | 0.73 |
| Total fat intake | | | | | | | | | | | | |
| Low | 1,351.2 | 116.0 | | | 60.5 | 14.0 | | | 1,290.7 | 109.3 | | |
| Medium | 1,198.6 | 90.5 | -11.3% | 0.45 | 62.9 | 10.9 | 4.0% | 0.98 | 1,135.7 | 85.2 | -12.0% | 0.40 |
| | | 118.5 | -13.2% | 0.54 | 72.9 | 14.3 | 20.6% | 0.80 | 1,100.4 | 111.6 | -14.7% | 0.46 |
| Ingh | -,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | 110.0 | 10.270 | 5.6 1 | ,, | 1 | 20.070 | 5.00 | 1,100.1 | | 1117/5 | 0. |

Table 5. Mib-1 expression in crypts of normal-appearing rectal mucosa of sporadic colorectal adenoma patients according to categories of participant characteristics (n = 104)^a.

| Saturated intake | d fat | | | | | | | | | | | | |
|----------------------------------|------------|---------|-------|--------|------|------|------|--------|------|---------|-------|--------|------|
| iniane | Low | 1,346.7 | 94.0 | | | 63.2 | 41.0 | | | 1,283.5 | 88.5 | | |
| | Medium | | 94.8 | -9.5% | 0.53 | 73.5 | 51.0 | 16.3% | 0.74 | 1,145.4 | 89.3 | -10.8% | 0.44 |
| | High | 1,154.5 | 95.2 | -14.3% | 0.29 | 60.1 | 37.5 | -5.0% | 0.97 | 1,094.4 | 89.7 | -14.7% | 0.26 |
| Red mea | t intake | | | | | | | | | | | | |
| | | 1,215.1 | 96.3 | | | 68.3 | 11.6 | | | 1,146.8 | 90.9 | | |
| | Medium | | 95.6 | -5.6% | 0.84 | 56.1 | 11.6 | -17.9% | 0.69 | 1,091.1 | 90.2 | -4.9% | 0.88 |
| | e | 1,357.6 | 97.8 | 11.7% | 0.51 | 71.1 | 11.8 | 4.1% | 0.98 | 1,286.5 | 92.2 | 12.2% | 0.49 |
| Processe intake | ed meat | | | | | | | | | | | | |
| | | 1,205.6 | 107.2 | | | 52.8 | 12.8 | | | - | 101.2 | | |
| | Medium | | 94.5 | -1.1% | 0.99 | 64.6 | 11.3 | 22.2% | 0.70 | 1,127.6 | 89.2 | -2.2% | 0.97 |
| | High | 1,325.1 | 116.8 | 9.9% | 0.73 | 79.2 | 13.9 | 49.9% | 0.37 | 1,245.9 | 110.3 | 8.1% | 0.80 |
| Fruit inte | | | | | | | | | | | | | |
| | | 1,378.0 | 104.6 | | | 86.1 | 12.4 | | | 1,291.9 | 99.1 | | |
| | Medium | | 87.7 | -7.5% | 0.65 | 69.9 | 10.4 | -18.8% | 0.49 | 1,204.3 | 83.1 | -6.8% | 0.71 |
| D: / / | U | 1,111.3 | 86.5 | -19.4% | 0.10 | 46.4 | 10.2 | -46.1% | 0.03 | 1,064.9 | 82.0 | -17.6% | 0.15 |
| Dietary f intake | nber | | | | | | | | | | | | |
| | Low | 1,429.4 | 96.4 | | | 82.1 | 11.8 | | | 1,347.3 | 90.8 | | |
| | Medium | 1,242.0 | 90.5 | -13.1% | 0.27 | 51.2 | 11.1 | -37.6% | 0.11 | 1,190.8 | 85.3 | -11.6% | 0.35 |
| | High | 1,043.1 | 98.3 | -27.0% | 0.02 | 62.2 | 12.0 | -24.2% | 0.44 | 980.9 | 92.6 | -27.2% | 0.02 |
| Total cal intake ^e | lcium | | | | | | | | | | | | |
| | Low | 1,440.8 | 118.5 | | | 89.5 | 14.0 | | | 1,351.3 | 112.2 | | |
| | Medium | 1,195.5 | 96.8 | -17.0% | 0.20 | 55.1 | 11.4 | -38.5% | 0.11 | 1,140.4 | 91.7 | -15.6% | 0.26 |
| | - | 1,143.6 | 114.8 | -20.6% | 0.20 | 49.9 | 13.6 | -44.3% | 0.14 | 1,093.7 | 108.8 | -19.1% | 0.25 |
| Serum 25 vitamin D |) f | | | | | | | | | | | | |
| | Low | 1,197.1 | 85.9 | | | 62.0 | 10.4 | | | 1,135.0 | 81.1 | | |

| Medium | 1,216.1 | 93.3 | 1.6% | 0.98 | 64.8 | 11.2 | 4.5% | 0.98 | 1,151.3 | 88.0 | 1.4% | 0.99 |
|--------|---------|-------|-------|------|------|------|-------|------|---------|-------|-------|------|
| High | 1,357.4 | 120.0 | 13.4% | 0.50 | 72.5 | 14.5 | 16.9% | 0.81 | 1,284.9 | 113.2 | 13.2% | 0.50 |

Abbreviations: OD, optical density; SE, standard error; NSAID, nonsteroidal anti-inflammatory drug.

^aResults presented as geometric means, adjusted for batch, age, race, total calcium, and total energy intake, multivitamin supplement use, non-aspirin NSAID use, and adenoma characteristics.

^bProportional difference defined as [(comparison group mean - reference group mean) / reference group mean] *100%.

^cP value for the difference between the comparison group and the reference group, from multivariable general linear model.

^dPhysical activity was measured by asking participants how much time they spend on moderate and vigorous activities during the past week, the results were converted to metabolic equivalents of task minutes (MET).

^eTotal calcium defined as dietary calcium plus supplement calcium intake.

| | | Who | le crypts | | Up | oper 40 | 0% of crypts | | Lo | wer 6 | 0% of crypts | |
|--------------------------------|---|-------|---|------|---|---------|---|------|---|-------|---|------|
| Participant characteristics | Mean biomarker expression (OD) | SE | Proportional difference ^b | | Mean biomarker expression (OD) | SE | Proportional difference ^b | | Mean biomarker expression (OD) | SE | Proportional difference ^b | |
| Current alcohol | | | | · | | | - | · | | | | • |
| intake ^f | | | | | | | | | | | | |
| None | 680.8 | 81.6 | | | 581.7 | 60.9 | | | 102.8 | 31.8 | | |
| Low | 733.5 | 75.2 | 7.7% | 0.85 | 623.3 | 56.1 | 7.1% | 0.83 | 105.7 | 29.3 | 2.9% | 1.00 |
| High | 675.1 | 83.2 | -0.8% | 1.00 | 577.9 | 62.0 | -0.7% | 1.00 | 74.8 | 32.4 | -27.2% | 0.78 |
| Multivitamin use | | | | | | | | | | | | |
| No | 753.0 | 753.0 | | | 657.2 | 65.3 | | | 76.7 | 34.2 | | |
| Yes | 668.4 | 668.4 | -11.2% | 0.47 | 562.7 | 44.1 | -14.4% | 0.28 | 104.5 | 23.1 | 36.2% | 0.54 |
| Non-aspirin NSAID use | | | | | | | | | | | | |
| None | 890.4 | 178.7 | | | 664.1 | 62.8 | | | 132.4 | 32.8 | | |
| Once a week | 639.0 | 64.3 | -28.2% | 0.29 | 567.8 | 45.6 | -14.5% | 0.39 | 76.5 | 23.8 | -42.2% | 0.32 |
| > once a week | 508.6 | 294.6 | -42.9% | 0.50 | 546.0 | 88.4 | -17.8% | 0.47 | 79.9 | 46.1 | -39.6% | 0.58 |
| Physical activity ^d | | | | | | | | | | | | |
| Low | 720.1 | 86.3 | | | 628.0 | 63.8 | | | 73.1 | 33.2 | | |
| Medium | 692.5 | 78.0 | -3.8% | 0.96 | 547.3 | 57.6 | -12.9% | 0.53 | 125.2 | 30.0 | 71.2% | 0.39 |
| High | 686.6 | 79.5 | -4.6% | 0.95 | 610.4 | 58.8 | -2.8% | 0.97 | 87.9 | 30.6 | 20.1% | 0.93 |
| Total fat intake | | | | | | | | | | | | |
| Low | 739.6 | 78.6 | | | 620.2 | 58.8 | | | 69.4 | 29.8 | | |
| Medium | | 78.0 | -1.2% | 1.00 | 590.3 | 58.3 | -4.8% | 0.91 | 148.0 | 29.5 | 113.1% | 0.12 |
| High | | 77.6 | -14.5% | 0.53 | 577.5 | 58.1 | -6.9% | 0.83 | 67.3 | 29.4 | -3.0% | 1.00 |
| Saturated fat | | | | | | | | | | | | |

Table 6. P21 expression in crypts of normal-appearing rectal mucosa of sporadic colorectal adenoma patients according to categories of participant characteristics (n = 104)^a.

intake

| Low | 780.7 | 78.0 | | | 646.4 | 58.6 | | | 142.3 | 30.5 | | |
|---------------------------------------|-------|-------|--------|------|-------|------|--------|------|-------|------|--------|------|
| Medium | 589.0 | 78.0 | -24.5% | 0.16 | 508.4 | 58.6 | -21.3% | 0.18 | 57.6 | 30.5 | -59.6% | 0.10 |
| High | 712.2 | 73.8 | -8.8% | 0.75 | 622.4 | 55.4 | -3.7% | 0.94 | 82.8 | 28.8 | -41.9% | 0.29 |
| Red meat intake | | | | | | | | | | | | |
| Low | 588.8 | 86.7 | | | 547.4 | 64.6 | | | 77.6 | 33.9 | | |
| Medium | 798.3 | 85.5 | 35.6% | 0.20 | 629.5 | 63.8 | 15.0% | 0.60 | 98.3 | 33.5 | 26.7% | 0.88 |
| High | 713.0 | 81.4 | 21.1% | 0.49 | 610.1 | 60.7 | 11.5% | 0.72 | 108.4 | 31.9 | 39.7% | 0.75 |
| Processed meat intake | | | | | | | | | | | | |
| Low | 617.7 | 85.7 | | | 573.2 | 63.1 | | | 108.6 | 33.6 | | |
| Medium | 789.6 | 88.1 | 27.8% | 0.27 | 685.8 | 64.9 | 19.6% | 0.34 | 82.7 | 34.6 | -23.9% | 0.81 |
| High | 713.1 | 97.6 | 15.4% | 0.76 | 546.4 | 71.9 | -4.7% | 0.96 | 90.0 | 38.3 | -17.1% | 0.93 |
| Fruit intake | | | | | | | | | | | | |
| Low | 708.4 | 84.4 | | | 554.9 | 63.0 | | | 96.4 | 33.2 | | |
| Medium | 744.5 | 73.2 | 5.1% | 0.93 | 660.3 | 54.6 | 19.0% | 0.34 | 118.4 | 28.8 | 22.8% | 0.83 |
| High | 643.2 | 74.5 | -9.2% | 0.80 | 562.1 | 55.6 | 1.3% | 0.99 | 70.2 | 29.3 | -27.1% | 0.78 |
| Dietary fiber intake | | | | | | | | | | | | |
| Low | 678.1 | 84.1 | | | 602.2 | 62.4 | | | 57.8 | 32.4 | | |
| Medium | 730.1 | 76.5 | 7.7% | 0.86 | 632.9 | 56.8 | 5.1% | 0.91 | 100.9 | 29.5 | 74.7% | 0.52 |
| High | 685.1 | 96.9 | 1.0% | 1.00 | 540.1 | 72.0 | -10.3% | 0.78 | 136.9 | 37.4 | 136.9% | 0.26 |
| Total calcium intake ^e | | | | | | | | | | | | |
| Low | 722.2 | 95.9 | | | 592.7 | 51.3 | | | 113.8 | 37.5 | | |
| Medium | 623.8 | 78.6 | -13.6% | 0.63 | 578.9 | 59.4 | -2.3% | 0.98 | 74.8 | 30.7 | -34.3% | 0.63 |
| High | 752.6 | 93.3 | 4.2% | 0.97 | 614.7 | 78.9 | 3.7% | 0.97 | 96.0 | 36.4 | -15.6% | 0.93 |
| Serum 25-OH vitamin D ^f | | | | | | | | | | | | |
| Low | 598.2 | 68.7 | | | 514.2 | 71.3 | | | 67.6 | 27.2 | | |
| Medium | 753.7 | 79.6 | 26.0% | 0.26 | 643.5 | 58.5 | 25.1% | 0.20 | 93.9 | 31.5 | 38.9% | 0.77 |
| High | 822.6 | 105.7 | 37.5% | 0.18 | 690.1 | 69.4 | 34.2% | 0.16 | 150.9 | 41.8 | 123.2% | 0.22 |

Abbreviations: OD, optical density; SE, standard error; NSAID, nonsteroidal anti-inflammatory drug.

^aResults presented as geometric means, adjusted for batch, age, race, total calcium, and total energy intake, multivitamin supplement use, non-aspirin NSAID use, and adenoma characteristics.

^bProportional difference defined as [(comparison group mean - reference group mean) / reference group mean] *100%.

^cP value for the difference between the comparison group and the reference group, from multivariable general linear model.

^dPhysical activity was measured by asking participants how much time they spend on moderate and vigorous activities during the past week, the results were converted to metabolic equivalents of task minutes (MET).

^eTotal calcium defined as dietary calcium plus supplement calcium intake.

Supplements

Supplement Table 1. Ratios of mean biomarker expression in crypts of normal-appearing rectal mucosa of sporadic colorectal adenoma patients according to categories of participant characteristics (n = 104)^a.

| | | BAX/BCL-2 | | | BAX/mib-1 | | | p21/mib-1 | |
|--------------------------------|---|---|---------|---|---|---------|---|---|----------------|
| Participant characteristics | Ratio of mean biomarke r expressio n | Proportion al difference ^b | P value | Ratio of mean biomarke r expressio n | Proportion al difference ^b | P value | Ratio of mean biomarke r expressio n | Proportion al difference ^b | <i>P</i> value |
| <i>Current alcohol intake</i> | | | | | | | | | |
| None | 0.74 | | | 0.49 | | | 0.62 | | |
| Low | 0.52 | -30.1% | 0.40 | 0.33 | -33.3% | 0.19 | 0.63 | 0.8% | 1.00 |
| High | 0.65 | -12.3% | 0.87 | 0.36 | -27.8% | 0.38 | 0.42 | -32.2% | 0.04 |
| Multivitamin use | | | | | | | | | |
| No | 0.70 | | | 0.34 | | | 0.59 | | |
| Yes Non-aspirin NSAID | 0.60 | -13.9% | 0.63 | 0.41 | 22.9% | 0.38 | 0.54 | -8.5% | 0.50 |
| use | | | | | | | | | |
| None | 0.56 | | | 0.38 | | | 0.60 | | |
| Once a week | 0.66 | 18.8% | 0.78 | 0.37 | -1.8% | 1.00 | 0.53 | -11.6% | 0.58 |
| > once a week | 0.69 | 24.4% | 0.81 | 0.48 | 27.2% | 0.65 | 0.61 | 1.5% | 0.99 |
| Physical activity ^d | | | | | | | | | |
| Low | 0.63 | | | 0.31 | | | 0.56 | | |
| Medium | 0.79 | 25.4% | 0.60 | 0.36 | 16.7% | 0.85 | 0.55 | -2.8% | 0.97 |
| High | 0.45 | -29.4% | 0.52 | 0.48 | 55.1% | 0.22 | 0.57 | 1.9% | 0.99 |
| Total fat intake | | | | | | | | | |
| Low | 0.65 | | | 0.32 | | | 0.52 | | |
| Medium | 0.44 | -31.6% | 0.43 | 0.40 | 23.4% | 0.69 | 0.64 | 22.0% | 0.28 |
| High | 0.80 | 22.8% | 0.68 | 0.44 | 36.5% | 0.61 | 0.53 | 1.0% | 1.00 |

| Saturated fat | intake | | | | | | | | | |
|---------------|------------|------|--------|------|------|--------|------|------|--------|------|
| | Low | 0.71 | | | 0.41 | | | 0.44 | | |
| | Medium | 0.33 | -52.7% | 0.08 | 0.28 | -31.9% | 0.33 | 0.54 | 21.2% | 0.40 |
| | High | 0.82 | 15.2% | 0.79 | 0.48 | 17.7% | 0.71 | 0.69 | 56.5% | 0.05 |
| Red meat inte | ake | | | | | | | | | |
| | Low | 0.57 | | | 0.37 | | | 0.51 | | |
| | Medium | 0.87 | 52.8% | 0.22 | 0.46 | 23.5% | 0.60 | 0.63 | 22.7% | 0.22 |
| | High | 0.47 | -16.7% | 0.84 | 0.33 | -10.7% | 0.90 | 0.54 | 5.5% | 0.90 |
| Processed me | eat intake | | | | | | | | | |
| | Low | 0.65 | | | 0.41 | | | 0.55 | | |
| | Medium | 0.70 | 8.9% | 0.94 | 0.42 | 1.9% | 1.00 | 0.67 | 21.1% | 0.22 |
| | High | 0.56 | -13.8% | 0.91 | 0.34 | -16.6% | 0.84 | 0.48 | -12.7% | 0.68 |
| Fruit intake | | | | | | | | | | |
| | Low | 0.76 | | | 0.37 | | | 0.53 | | |
| | Medium | 0.53 | -29.7% | 0.41 | 0.37 | 0.4% | 1.00 | 0.61 | 14.9% | 0.51 |
| | High | 0.64 | -15.9% | 0.77 | 0.43 | 17.1% | 0.78 | 0.54 | 2.3% | 0.98 |
| Dietary fiber | | | | | | | | | | |
| | Low | 0.70 | | | 0.39 | | | 0.51 | | |
| | Medium | 0.66 | -6.1% | 0.96 | 0.40 | 0.7% | 1.00 | 0.62 | 23.1% | 0.22 |
| | High | 0.50 | -28.6% | 0.96 | 0.38 | -3.1% | 0.99 | 0.55 | 9.3% | 0.82 |
| Total calciun | | | | | | | | | | |
| | Low | 0.79 | | | 0.40 | | | 0.58 | | |
| | Medium | 0.48 | -38.8% | 0.18 | 0.41 | 2.0% | 1.00 | 0.56 | -2.7% | 0.97 |
| | High | 0.63 | -19.9% | 0.65 | 0.35 | -11.6% | 0.89 | 0.55 | -4.5% | 0.95 |
| Serum 25-OH | vitamin D | | | | | | | | | |
| | Low | 0.61 | | | 0.38 | | | 0.48 | | |
| | Medium | 0.55 | -9.9% | 0.93 | 0.35 | -7.1% | 0.95 | 0.63 | 30.0% | 0.08 |
| | High | 0.80 | 30.6% | 0.64 | 0.47 | 24.2% | 0.61 | 0.63 | 30.9% | 0.15 |

Abbreviations: OD, optical density; SE, standard error; NSAID, nonsteroidal anti-inflammatory drug.

^aResults presented as geometric means, adjusted for batch, age, race, total calcium, and total energy intake, multivitamin supplement use, non-aspirin NSAID use, and adenoma characteristics.

^bProportional difference defined as [(comparison group mean - reference group mean) / reference group mean] *100%.

^cP value for the difference between the comparison group and the reference group, from multivariable general linear model.

^dPhysical activity was measured by asking participants how much time they spend on moderate and vigorous activities during the past week, the results were converted to metabolic equivalents of task minutes (MET).

^eTotal calcium defined as dietary calcium plus supplement calcium intake.

| | | BAX | | | Bcl-2 | | | Mib-1 | | | p21 | |
|-------------------------------------|------|---|------------|------|---|-----------------|------|---|-----------------|------|---|-----------------|
| Participant characteristics | φh | Proportional difference ^b | P value | φh | Proportional difference ^b | P value c | φh | Proportional difference ^b | P value c | φh | Proportional difference ^b | P value c |
| Current alcohol intake ^f | | | | | | | | | | | | |
| None | 0.30 | | | 0.09 | | | 0.05 | | | 0.89 | | |
| Low | 0.32 | 3.7% | 0.95 | 0.07 | -23.0% | 0.61 | 0.05 | -1.0% | 1.00 | 0.90 | 1.2% | 0.91 |
| High | 0.37 | 20.0% | 0.32 | 0.06 | -34.7% | 0.39 | 0.06 | 17.4% | 0.68 | 0.91 | 2.7% | 0.65 |
| Multivitamin use | | | | | | | | | | | | |
| No | 0.33 | | | 0.08 | | | 0.06 | | | 0.92 | | |
| Yes | 0.33 | -0.7% | 0.95 | 0.07 | -6.9% | 0.82 | 0.05 | -13.7% | 0.38 | 0.89 | -2.6% | 0.44 |
| Non-aspirin NSAID use | | | | | | | | | | | | |
| None | 0.32 | | | 0.11 | | | 0.05 | | | 0.87 | | |
| Once a week | 0.31 | -5.1% | 0.89 | 0.06 | -44.8% | 0.05 | 0.05 | 10.9% | 0.79 | 0.92 | 6.0% | 0.11 |
| > once a week | 0.43 | 33.8% | 0.11 | 0.07 | -32.9% | 0.37 | 0.04 | -20.3% | 0.68 | 0.89 | 2.8% | 0.75 |
| <i>Physical activity</i> | | | | | | | | | | | | |
| Low | 0.27 | | | 0.07 | | | 0.05 | | | 0.92 | | |
| Medium | 0.31 | 15.5% | 0.53 | 0.09 | 27.1% | 0.63 | 0.05 | -1.1% | 1.00 | 0.88 | -3.9% | 0.36 |
| High | 0.39 | 44.8% | 0.02 | 0.06 | -11.0% | 0.92 | 0.05 | -12.8% | 0.75 | 0.90 | -2.4% | 0.69 |
| Total fat intake | | | | | | | | | | | | |
| Low | 0.35 | | | 0.07 | | | 0.05 | | | 0.92 | | |
| Medium | 0.31 | -13.0% | 0.47 | 0.08 | 18.4% | 0.80 | 0.05 | 0.0% | 1.00 | 0.86 | -7.0% | 0.04 |
| High | 0.32 | -9.0% | 0.71 | 0.08 | 17.3% | 0.87 | 0.06 | 20.9% | 0.71 | 0.92 | -0.1% | 1.00 |
| Saturated fat intake | | | | | | | | | | | | |
| Low | 0.32 | | | 0.07 | | | 0.04 | | | 0.87 | | |
| | | | | | | | | | | | | |

Supplement Table 2. Mean biomarker expression in ϕh^a of crypts of normal-appearing rectal mucosa of sporadic colorectal adenoma patients according to categories of participant characteristics (n = 104).

| Medium | 0.31 | -3.3% | 0.96 | 0.08 | 14.0% | 0.87 | 0.06 | 31.7% | 0.27 | 0.92 | 4.7% | 0.27 |
|---------------------------------------|------|--------|------|------|--------|------|------|--------|------|------|-------|------|
| High | 0.35 | 10.7% | 0.67 | 0.08 | 9.1% | 0.95 | 0.05 | 10.4% | 0.87 | 0.91 | 4.2% | 0.34 |
| Red meat intake | | | | | | | | | | | | |
| Low | 0.32 | | | 0.06 | | | 0.05 | | | 0.92 | | |
| Medium | 0.32 | -0.1% | 1.00 | 0.07 | 19.6% | 0.83 | 0.05 | -5.3% | 0.95 | 0.90 | -1.9% | 0.82 |
| High | 0.34 | 6.3% | 0.88 | 0.09 | 45.1% | 0.44 | 0.05 | -3.2% | 0.98 | 0.89 | -3.2% | 0.56 |
| Processed meat intake | | | | | | | | | | | | |
| Low | 0.36 | | | 0.09 | | | 0.04 | | | 0.89 | | |
| Medium | 0.29 | -18.6% | 0.24 | 0.07 | -20.5% | 0.68 | 0.05 | 18.9% | 0.67 | 0.91 | 1.6% | 0.87 |
| High | 0.33 | -6.8% | 0.88 | 0.06 | -30.4% | 0.60 | 0.06 | 47.0% | 0.27 | 0.90 | 0.8% | 0.97 |
| Fruit intake | | | | | | | | | | | | |
| Low | 0.33 | | | 0.08 | | | 0.06 | | | 0.90 | | |
| Medium | 0.34 | 2.9% | 0.97 | 0.09 | 18.7% | 0.79 | 0.05 | -14.8% | 0.58 | 0.88 | -2.2% | 0.71 |
| High | 0.31 | -7.1% | 0.81 | 0.06 | -16.2% | 0.83 | 0.04 | -33.0% | 0.11 | 0.91 | 1.0% | 0.94 |
| Dietary fiber intake | | | | | | | | | | | | |
| Low | 0.36 | | | 0.07 | | | 0.05 | | | 0.93 | | |
| Medium | 0.37 | 2.9% | 0.96 | 0.11 | 66.8% | 0.09 | 0.04 | -16.0% | 0.64 | 0.89 | -3.9% | 0.37 |
| High | 0.26 | -25.8% | 0.13 | 0.04 | -40.0% | 0.57 | 0.06 | 8.2% | 0.91 | 0.87 | -5.8% | 0.23 |
| Total calcium intake ^e | | | | | | | | | | | | |
| Low | 0.34 | | | 0.09 | | | 0.06 | | | 0.89 | | |
| Medium | 0.34 | 1.7% | 0.98 | 0.08 | -10.3% | 0.90 | 0.04 | -27.6% | 0.27 | 0.91 | 2.3% | 0.73 |
| High | 0.35 | 5.1% | 0.88 | 0.05 | -43.9% | 0.36 | 0.05 | -18.5% | 0.64 | 0.91 | 2.1% | 0.84 |
| Serum 25-OH vitamin D ^f | | | | | | | | | | | | |
| Low | 0.33 | | | 0.07 | | | 0.05 | | | 0.91 | | |
| Medium | 0.30 | -10.6% | 0.65 | 0.07 | 0.5% | 1.00 | 0.05 | 10.5% | 0.83 | 0.90 | -1.0% | 0.93 |
| High | 0.37 | 11.7% | 0.62 | 0.08 | 14.1% | 0.92 | 0.05 | 4.8% | 0.97 | 0.88 | -3.6% | 0.58 |

Abbreviations: SE, standard error; NSAID, nonsteroidal anti-inflammatory drug.

 $_{a}\phi h$ is the ratio of mean biomarker expression in upper 40% of crypts relative to that in whole crypts, adjusted for batch, age, race, total calcium, and total energy intake, multivitamin supplement use, non-aspirin NSAID use, and adenoma characteristics.

^b Proportional difference defined as [(comparison group value - reference group value)/ reference group value] *100%.

_c P value for the difference between the comparison group and the reference group, from general linear model.

^d Physical activity was measured by asking participants how much time they spend on moderate and vigorous activities during the past week, the results were converted to the metabolic equivalent of task minutes (MET).

^eTotal calcium defined as dietary calcium plus supplement calcium intake

| | | | Who | le crypts | | Up | per 4(|)% of crypts | | Low | ver 60 |)% of crypts | |
|--------------------------------|------------|---|------|---|-------------------|---|--------|---|------------|---|--------|---|-------------------|
| Participant characteristics | | Mean biomarker expression (OD) | SE | Proportional difference ^b | <i>P</i> value | Mean biomarker expression (OD) | SE | Proportional difference ^b | P value | Mean biomarker expression (OD) | SE | Proportional difference ^b | <i>P</i> value |
| Age ^e | | | | | | | | | | | | | |
| | Low | 366.8 | 61.3 | | | 139.9 | 26.6 | | | 243.1 | 40.7 | | |
| | Medium | 365.9 | 55.1 | -0.3% | 1.00 | 127.1 | 23.9 | -9.2% | 0.91 | 227.5 | 36.6 | -6.4% | 0.94 |
| | High | 559.0 | 57.8 | 52.4% | 0.05 | 180.1 | 25.0 | 28.7% | 0.46 | 356.7 | 38.4 | 46.7% | 0.10 |
| Sex | | | | | | | | | | | | | |
| | Male | 408.6 | 51.4 | | | 154.2 | 21.8 | | | 250.6 | 34.2 | | |
| | Female | 456.5 | 48.6 | 11.7% | 0.53 | 144.5 | 20.7 | -6.3% | 0.76 | 299.7 | 32.4 | 19.6% | 0.33 |
| Race | | | | | | | | | | | | | |
| | White | 451.0 | 38.7 | | | 155.5 | 16.4 | | | 280.8 | 25.9 | | |
| | Other race | 378.4 | 74.1 | -16.1% | 0.40 | 128.0 | 31.4 | -17.7% | 0.45 | 261.4 | 49.6 | -6.9% | 0.74 |
| Education ^e | | | | | | | | | | | | | |
| | Low | 536.6 | 57.8 | | | 151.6 | 24.8 | | | 359.4 | 37.7 | | |
| | Medium | 364.0 | 56.9 | -32.2% | 0.08 | 125.5 | 24.4 | -17.2% | 0.69 | 233.6 | 37.2 | -35.0% | 0.04 |
| | High | 390.2 | 65.3 | -27.3% | 0.21 | 175.5 | 28.0 | 15.7% | 0.76 | 221.9 | 42.7 | -38.2% | 0.04 |
| BMI ^e | | | | | | | | | | | | | |
| | Low | 469.6 | 72.3 | | | 161.7 | 30.7 | | | 292.5 | 48.4 | | |
| | Medium | 448.5 | 53.1 | -4.5% | 0.96 | 157.2 | 22.5 | -2.8% | 0.99 | 288.2 | 35.5 | -1.5% | 1.00 |
| | High | 397.2 | 55.2 | -15.4% | 0.64 | 133.2 | 23.4 | -17.6% | 0.67 | 254.3 | 36.9 | -13.1% | 0.74 |
| Vegetable intak | te | | | | | | | | | | | | |
| | Low | 422.1 | 55.6 | | | 132.5 | 23.0 | | | 289.6 | 37.4 | | |

Supplement Table 3. BAX expression in crypts of normal-appearing rectal mucosa of sporadic colorectal adenoma patients according to additional categories of participant characteristics (n = 104)^a.

| | Medium | 473.6 | 59.6 | 12.2% | 0.76 | 196.1 | 24.7 | 48.0% | 0.12 | 277.6 | 40.1 | 7.4% | 0.96 |
|----------------------|----------|-------|------|--------|------|-------|------|-------|------|-------|------|-------|------|
| | High | 379.5 | 60.9 | -10.1% | 0.83 | 120.9 | 25.2 | -8.7% | 0.92 | 258.6 | 41.0 | 9.6% | 0.91 |
| Current smoker | | | | | | | | | | | | | |
| | Low | 408.7 | 44.2 | | | 142.2 | 18.8 | | | 265.6 | 29.6 | | |
| | Medium | 467.6 | 51.4 | 14.4% | 0.40 | 158.4 | 21.8 | 11.4% | 0.58 | 290.8 | 34.4 | 9.5% | 0.58 |
| Adenoma ^d | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | Low risk | 391.3 | 43.7 | | | 142.8 | 18.6 | | | 249.3 | 29.2 | | |
| | High | 478.8 | 55.6 | 22.4% | 0.24 | 158.9 | 23.6 | 11.2% | 0.61 | 318.5 | 37.2 | 27.8% | 0.16 |

^aResults presented as geometric means, adjusted for batch, age, race, total calcium, and total energy intake, multivitamin supplement use, non-aspirin NSAID use, and adenoma characteristics.

^bProportional difference defined as [(comparison group mean - reference group mean) / reference group mean] *100%. ^cP value for the difference between the comparison group and the reference group, from multivariable general linear model.

^dLow-risk adenoma defined as with less or equal than one and no advanced adenoma, high-risk adenoma defined as with multiple adenomas or with at least one advanced adenoma

| | | | Who | le crypts | | Upj | per 40 | % of crypts | | Lo | wer 60 |)% of crypts | |
|--------------------------------|------------|---|-------|--|------|---|--------|--|------|---|--------|--|------|
| Participant characteristics | | Mean biomarker expression (OD) | | Proportiona difference ¹ | | Mean biomarker expression (OD) | | Proportiona difference ^b | | Mean biomarker expression (OD) | | Proportiona difference ^b | |
| Age ^e | | | | | | · · · | | | | | | | |
| | Low | 850.0 | 104.5 | i | | 62.3 | 22.9 | | | 787.7 | 90.6 | | |
| | Medium | 763.8 | 99.3 | -10.1% | 0.78 | 70.1 | 21.7 | 12.5% | 0.96 | 693.7 | 86.1 | -11.9% | 0.68 |
| | High | n 884.3 | 98.9 | 4.0% | 0.96 | 68.5 | 21.6 | 9.9% | 0.97 | 815.8 | 85.7 | 3.6% | 0.97 |
| Sex | | | | | | | | | | | | | |
| | Male | e 783.6 | 84.1 | | | 42.2 | 18.3 | | | 741.5 | 73.1 | | |
| | Female | 882.7 | 85.5 | 12.6% | 0.46 | 93.0 | 18.6 | 120.5% | 0.09 | 789.7 | 74.3 | 6.5% | 0.68 |
| Race | | | | | | | | | | | | | |
| | White | 825.0 | 62.5 | | | 73.6 | 13.5 | | | 751.3 | 54.3 | | |
| | Other race | 860.2 | 135.7 | 4.3% | 0.83 | 43.7 | 29.4 | -40.7% | 0.39 | 816.6 | 117.8 | 8 8.7% | 0.64 |
| Education ^e | | | | | | | | | | | | | |
| | Low | 912.6 | 94.2 | | | 67.8 | 20.5 | | | 844.8 | 81.6 | | |
| | Medium | n 795.0 | 96.2 | -12.9% | 0.62 | 51.8 | 20.9 | -23.5% | 0.82 | 743.2 | 83.3 | -12.0% | 0.62 |
| | High | n 772.0 | 109.1 | -15.4% | 0.55 | 85.6 | 23.7 | 26.2% | 0.81 | 686.5 | 94.4 | -18.7% | 0.38 |
| BMI ^e | | | | | | | | | | | | | |
| | Low | 820.0 | 120.8 | 5 | | 50.5 | 26.6 | | | 769.5 | 105.2 | 2 | |
| | Medium | 873.1 | 92.2 | 6.5% | 0.91 | 63.0 | 20.3 | 24.8% | 0.90 | 810.1 | 80.3 | 5.3% | 0.93 |
| | High | n 802.3 | 84.0 | -2.2% | 0.99 | 79.7 | 18.5 | 58.0% | 0.54 | 722.5 | 73.2 | -6.1% | 0.90 |
| Vegetable intak | e | | | | | | | | | | | | |
| | Low | 732.1 | 92.2 | | | 40.1 | 19.7 | | | 692.0 | 80.4 | | |
| | Medium | 836.5 | 100.5 | 14.3% | 0.69 | 82.0 | 21.5 | 104.6% | 0.30 | 754.5 | 87.6 | 9.0% | 0.84 |

Supplement Table 4. Bcl-2 expression in crypts of normal-appearing rectal mucosa of sporadic colorectal adenoma patients according to additional categories of participant characteristics (n = 104)^a.

| | High | 955.7 | 103.1 | 30.5% | 0.20 | 85.1 | 22.0 | 112.3% | 0.24 | 870.7 | 89.8 | 25.8% | 0.26 |
|----------------------|----------|-------|-------|-------|------|------|------|--------|------|-------|------|-------|------|
| Current smoker | | | | | | | | | | | | | |
| | Low | 856.7 | 74.0 | | | 59.8 | 16.2 | | | 796.9 | 64.2 | | |
| | Medium | 801.7 | 84.8 | -6.4% | 0.65 | 76.7 | 18.5 | 28.3% | 0.52 | 725.0 | 73.6 | -9.0% | 0.49 |
| Adenoma ^d | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | Low risk | 822.4 | 73.3 | | | 58.9 | 15.9 | | | 763.5 | 63.7 | | |
| | High | 846.7 | 89.5 | 3.0% | 0.84 | 79.1 | 19.4 | 34.2% | 0.45 | 767.7 | 77.8 | 0.5% | 0.97 |

^aResults presented as geometric means, adjusted for batch, age, race, total calcium, and total energy intake, multivitamin supplement use, non-aspirin NSAID use, and adenoma characteristics.

^bProportional difference defined as [(comparison group mean - reference group mean) / reference group mean] *100%. ^cP value for the difference between the comparison group and the reference group, from multivariable general linear model.

^dLow-risk adenoma defined as with less or equal than one and no advanced adenoma, high-risk adenoma defined as with multiple adenomas or with at least one advanced adenoma

| | | Who | le crypts | | Up | per 40 |)% of crypts | | Lo | wer 6(|)% of crypts | |
|--------------------------------|---|-------|---|------|---|--------|---|------|---|--------|---|------|
| Participant characteristics | Mean biomarker expression (OD) | | Proportional difference ^b | | Mean biomarker expression (OD) | SE | Proportional difference ^b | | Mean biomarker expression (OD) | SE | Proportional difference ^b | |
| Age ^e | | | | | | | | | | | | |
| Lov | v 1,148.8 | 99.1 | | | 64.5 | 11.9 | | | 1084.3 | 93.5 | | |
| Mediur | n 1,306.0 | 89.6 | 13.7% | 0.40 | 74.4 | 10.7 | 15.4% | 0.76 | 1231.6 | 84.5 | 13.6% | 0.40 |
| Hig | h 1,254.6 | 91.4 | 9.2% | 0.65 | 56.8 | 10.9 | -11.9% | 0.85 | 1197.8 | 86.2 | 10.5% | 0.58 |
| Sex | | | | | | | | | | | | |
| Mal | e 1,269.8 | 79.9 | | | 62.6 | 9.6 | | | 1207.2 | 75.3 | | |
| Femal | e 1,213.9 | 75.8 | -4.4% | 0.63 | 67.9 | 9.1 | 8.5% | 0.70 | 1146.0 | 71.4 | -5.1% | 0.57 |
| Race | | | | | | | | | | | | |
| Whit | e 1,248.3 | 61.5 | | | 63.6 | 7.4 | | | 1184.6 | 58.0 | | |
| Other rac | e 1,214.7 | 117.9 | -2.7% | 0.81 | 71.1 | 14.1 | 11.7% | 0.65 | 1143.7 | 111.2 | -3.5% | 0.75 |
| Education ^e | | | | | | | | | | | | |
| Lov | v 1,298.7 | 87.8 | | | 60.6 | 10.5 | | | 1238.1 | 82.9 | | |
| Mediur | n 1,305.4 | 89.1 | 0.5% | 1.00 | 81.9 | 10.6 | 35.1% | 0.27 | 1223.4 | 84.2 | -1.2% | 0.99 |
| Hig | h 1,082.8 | 102.6 | -16.6% | 0.21 | 50.7 | 12.2 | -16.4% | 0.77 | 1032.1 | 97.0 | -16.6% | 0.21 |
| BMI ^e | | | | | | | | | | | | |
| Lov | v 1,153.8 | 116.1 | | | 62.0 | 13.8 | | | 1091.8 | 109.5 | | |
| Mediur | n 1,170.1 | 85.2 | 1.4% | 0.99 | 63.3 | 10.1 | 2.1% | 1.00 | 1106.8 | 80.3 | 1.4% | 0.99 |
| Hig | h 1,365.8 | 88.4 | 18.4% | 0.25 | 69.6 | 10.5 | 12.3% | 0.86 | 1296.2 | 83.3 | 18.7% | 0.23 |
| Vegetable intake | | | | | | | | | | | | |
| Lov | v 1,279.6 | 88.6 | | | 66.0 | 10.5 | | | 1213.6 | 83.7 | | |
| Mediur | n 1,181.3 | 97.8 | -7.7% | 0.70 | 53.5 | 11.6 | -18.9% | 0.66 | 1127.8 | 92.3 | -7.1% | 0.73 |
| Hig | h 1,253.6 | 97.5 | -2.0% | 0.97 | 77.0 | 11.6 | 16.6% | 0.71 | 1176.6 | 92.0 | -3.0% | 0.94 |
| Current smoker | | | | | | | | | | | | |

Supplement Table 5. Mib-1 expression in crypts of normal-appearing rectal mucosa of sporadic colorectal adenoma patients according to additional categories of participant characteristics (n = 104)^a.

| | Low | 1,196.3 | 69.6 | | | 64.5 | 8.4 | | | 1131.8 | 65.6 | | |
|--------|-----------------|---------|------|-------|------|------|------|------|------|--------|------|-------|------|
| | Medium | 1,299.9 | 80.8 | 8.7% | 0.34 | 66.5 | 9.7 | 3.1% | 0.88 | 1233.3 | 76.2 | 9.0% | 0.32 |
| Adenon | na ^d | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | Low risk | 1,192.5 | 69.7 | | | 65.4 | 8.4 | | | 1127.1 | 65.7 | | |
| | High | 1,315.5 | 89.0 | 10.3% | 0.30 | 65.4 | 10.7 | 0.0% | 1.00 | 1250.1 | 83.9 | 10.9% | 0.27 |

^aResults presented as geometric means, adjusted for batch, age, race, total calcium, and total energy intake, multivitamin supplement use, non-aspirin NSAID use, and adenoma characteristics.

^bProportional difference defined as [(comparison group mean - reference group mean) / reference group mean] *100%.

^cP value for the difference between the comparison group and the reference group, from multivariable general linear model.

^dLow-risk adenoma defined as with less or equal than one and no advanced adenoma, high-risk adenoma defined as with multiple adenomas or with at least one advanced adenoma

| | | le crypts | | Up |)% of crypts | Lower 60% of crypts | | | | | | |
|--------------------------------|---|-----------|---|------|---|---------------------|---|------|---|------|--|------|
| Participant characteristics | Mean biomarker expression (OD) | SE | Proportional difference ^b | | Mean biomarker expression (OD) | SE | Proportional difference ^b | | Mean biomarker expression (OD) | SE | Proportional difference ^b | |
| Age ^e | | | | | . , | | | | | | | |
| Lov | 692.3 | 85.3 | | | 625.4 | 63.6 | | | 66.9 | 33.0 | | |
| Mediun | 698.2 | 76.6 | 0.9% | 1.00 | 578.7 | 57.1 | -7.5% | 0.81 | 119.5 | 29.6 | 78.6% | 0.40 |
| Higl | 681.1 | 75.9 | -1.6% | 0.99 | 587.1 | 56.6 | -6.1% | 0.87 | 94.0 | 29.4 | 40.6% | 0.77 |
| Sex | | | | | | | | | | | | |
| Male | e 644.4 | 66.8 | | | 577.4 | 50.0 | | | 66.9 | 25.8 | | |
| Female | e 737.5 | 67.8 | 14.5% | 0.37 | 613.9 | 50.8 | 6.3% | 0.64 | 123.6 | 26.2 | 84.6% | 0.16 |
| Race | | | | | | | | | | | | |
| White | e 707.4 | 49.8 | | | 604.4 | 37.1 | | | 103.0 | 19.5 | | |
| Other race | 627.3 | 101.2 | -11.3% | 0.49 | 562.3 | 75.4 | -7.0% | 0.63 | 65.0 | 39.6 | -36.9% | 0.41 |
| Education ^e | | | | | | | | | | | | |
| Lov | 773.1 | 75.5 | | | 630.6 | 56.4 | | | 142.5 | 29.1 | | |
| Mediun | 678.1 | 77.9 | -12.3% | 0.61 | 620.7 | 58.2 | -1.6% | 0.99 | 57.5 | 30.0 | -59.7% | 0.10 |
| High | n 595.1 | 86.7 | -23.0% | 0.24 | 517.4 | 64.8 | -17.9% | 0.34 | 77.7 | 33.4 | -45.5% | 0.27 |
| BMI ^e | | | | | | | | | | | | |
| Lov | 651.0 | 99.1 | | | 574.2 | 73.6 | | | 76.8 | 38.6 | | |
| Mediun | 681.7 | 77.7 | 4.7% | 0.96 | 566.2 | 57.7 | -1.4% | 0.99 | 115.4 | 30.2 | 50.3% | 0.65 |
| Higl | n 718.4 | 71.4 | 10.3% | 0.79 | 632.8 | 53.1 | 10.2% | 0.73 | 85.7 | 27.8 | 11.5% | 0.97 |
| Vegetable intake | | | | | | | | | | | | |
| Lov | 623.3 | 74.8 | | | 573.0 | 56.0 | | | 50.3 | 28.8 | | |
| Mediun | n 765.7 | 79.1 | 22.8% | 0.35 | 646.6 | 59.2 | 12.8% | 0.60 | 119.2 | 30.4 | 137.0% | 0.21 |
| Higl | n 689.9 | 82.6 | 10.7% | 0.78 | 565.8 | 61.9 | -1.3% | 0.99 | 124.1 | 31.8 | 146.8% | 0.17 |
| Current smoker | | | | | | | | | | | | |

Supplement Table 6. P21 expression in crypts of normal-appearing rectal mucosa of sporadic colorectal adenoma patients according to additional categories of participant characteristics (n = 104)^a.

| | Low | 674.5 | 59.0 | | | 587.9 | 44.0 | | | 86.6 | 23.0 | | |
|----------------------|----------|-------|------|-------|------|-------|------|-------|------|-------|------|--------|------|
| | Medium | 710.5 | 66.8 | 5.3% | 0.69 | 605.0 | 49.8 | 2.9% | 0.80 | 105.5 | 26.1 | 21.8% | 0.59 |
| Adenoma ^d | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | Low risk | 711.4 | 59.5 | | | 606.5 | 44.4 | | | 104.8 | 23.2 | | |
| | High | 660.5 | 72.4 | -7.2% | 0.61 | 579.7 | 54.0 | -4.4% | 0.72 | 80.8 | 28.3 | -22.9% | 0.54 |

^aResults presented as geometric means, adjusted for batch, age, race, total calcium, and total energy intake, multivitamin supplement use, non-aspirin NSAID use, and adenoma characteristics.

^bProportional difference defined as [(comparison group mean - reference group mean) / reference group mean] *100%.

^cP value for the difference between the comparison group and the reference group, from multivariable general linear model.

^dLow-risk adenoma defined as with less or equal than one and no advanced adenoma, high-risk adenoma defined as with multiple adenomas or with at least one advanced adenoma